🎤 Upcoming Biotech Conferences
Biotech Dilution Watch
Every shelf registration, at-the-market program and equity offering filed on SEC EDGAR by the 729 biotech and pharma companies BioRadar tracks, combined with cash runway and upcoming FDA decisions into one transparent pressure score.
Of the 729 companies we track, 439 have filed an at-the-market (ATM) program in the last three years, which lets them sell new shares into the market on any trading day while the program has room. 198 have twelve months of cash or less at their last reported balance sheet. 1 combines thin cash, a financing tool already on file and an FDA decision within 120 days. That is the combination to watch: a company that needs money and can issue quickly often does so right after a catalyst, when the share price and trading volume are highest.
How to read this. The score (0 to 100) adds up named parts: cash runway (up to 40), an ATM program on file (15), a shelf registration (10), share-count growth over a year (up to 20) and an FDA decision ahead (up to 15), minus 10 when an offering came after the last balance sheet. Click a score to see its parts. Full method
Two limits to keep in mind. Cash comes from each company's latest 10-Q or 10-K, so each row shows the balance-sheet date and flags offerings filed after it. An ATM figure is the program's maximum when it was filed; how much has been sold since, and how much room is left, is not disclosed in structured filings.
Filings checked daily on SEC EDGAR. Last update Nov 17, 2026, 14:33 UTC.
Thin cash, financing on file, FDA decision within 120 days
| Score | Company | Cash runway | Financing on file | FDA decision |
|---|---|---|---|---|
| 100 | PYPDPolyPid Ltd. | 3 months$6.6M as of Dec 31, 2025 | ATM, max $8.3M | Nov 28, 2026in 10 days |
Dilution pressure ranking
| cash at last balance sheet | ATM programmax size when filed; amount left not disclosed | Shelf | Last raise | ||||
|---|---|---|---|---|---|---|---|
| CVKDCadrenal Therapeutics, Inc. | 3 months$2.4M as of Sep 30, 2026 | Dec 23, 2025max $5.1M | Mar 12, 2024S-3, $100M | +99% | None scheduled | Jul 1, 2026Private placement | |
CVKD: 100 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PYPDPolyPid Ltd. | 3 months$6.6M as of Dec 31, 2025 | Nov 8, 2024max $8.3Mfiled over 2 years ago | Jul 2, 2024F-3 | +79% | Nov 28, 2026in 10 days | Nov 26, 2025Direct / best efforts | |
PYPD: 100 points, High
Thin cash, a financing tool on file and an FDA decision within 120 days. |
|||||||
| COSMCosmos Health Inc. | 4 months$1.8M as of Jun 30, 2026 | Nov 7, 2025max $100M | Nov 7, 2025S-3, $200M | +233% | None scheduled | Aug 11, 2025Private placement | |
COSM: 100 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| GNLXGENELUX Corp | 5 months$10M as of Sep 30, 2026 | Mar 19, 2026max $100M | Feb 2, 2024S-3, $100M | +26% | None scheduled | May 24, 2024Underwritten, $28M | |
GNLX: 94 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ANVSAnnovis Bio, Inc. | 0 months$2.8M as of Sep 30, 2026Offering filed Nov 5, 2026, after this date | Feb 4, 2025max $250M | Feb 1, 2024S-3, $250M | +134% | None scheduled | Nov 5, 2026Underwritten | |
ANVS: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| INMInMed Pharmaceuticals Inc. | 2 months$1.1M as of Sep 30, 2026Offering filed Nov 10, 2026, after this date | Apr 3, 2026max $1.2M | Mar 20, 2026S-3, $50M | +96% | None scheduled | Nov 10, 2026Private placement | |
INM: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MTRIInMed Pharmaceuticals Inc. | 2 months$1.1M as of Sep 30, 2026Offering filed Nov 10, 2026, after this date | Apr 3, 2026max $1.2M | Mar 20, 2026S-3, $50M | +96% | None scheduled | Nov 10, 2026Private placement | |
MTRI: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ACTUACTUATE THERAPEUTICS, INC. | 2 months$2.1M as of Sep 30, 2026Offering filed Oct 28, 2026, after this date | Nov 28, 2025max $100M | Sep 2, 2025S-3 | +160% | None scheduled | Oct 28, 2026Underwritten, $11M | |
ACTU: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MGRXMANGOCEUTICALS, INC. | 2 months$0.7M as of Sep 30, 2026Offering filed Oct 1, 2026, after this date | Oct 9, 2026size not stated | Jun 13, 2025S-3, $150M | +60% | None scheduled | Oct 1, 2026Private placement | |
MGRX: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| TRAWTraws Pharma, Inc. | 3 months$5.0M as of Sep 30, 2026Offering filed Oct 23, 2026, after this date | May 22, 2026max $3.1M | Jul 1, 2026S-3, $139M | +92% | None scheduled | Oct 23, 2026Private placement | |
TRAW: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| SNTISenti Biosciences Holdings, Inc. | 4 months$13M as of Sep 30, 2026Offering filed Nov 10, 2026, after this date | May 1, 2026max $18M | Mar 21, 2025S-3, $18M | +226% | None scheduled | Nov 10, 2026Private placement | |
SNTI: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| BCDABioCardia, Inc. | 4 months$2.2M as of Jun 30, 2026 | Oct 24, 2025size not stated | None | +161% | None scheduled | Sep 19, 2025Direct / best efforts, $6.0M | |
BCDA: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| IMNNImunon, Inc. | 4 months$4.0M as of Sep 30, 2026Offering filed Oct 27, 2026, after this date | Mar 23, 2026max $17M | May 15, 2024S-3, $5.5M | +111% | None scheduled | Oct 27, 2026Direct / best efforts | |
IMNN: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| BTAIBioXcel Therapeutics, Inc. | 4 months$13M as of Jun 30, 2026 | Aug 18, 2025max $12M | None | +115% | None scheduled | Apr 17, 2026Private placement | |
BTAI: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PLURPluri Inc. | 6 months$8.7M as of Sep 30, 2026Offering filed Oct 30, 2026, after this date | Feb 13, 2024max $10Mfiled over 2 years ago | Sep 11, 2026S-3, $200M | +55% | None scheduled | Oct 30, 2026Private placement | |
PLUR: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| NMADNOMAD POWER SOLUTIONS, INC. | 6 months$5.6M as of Sep 30, 2026 | Jan 10, 2025size not stated | Apr 23, 2024S-3, $50M | +223% | None scheduled | Sep 30, 2026Private placement | |
NMAD: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| NRXPNRX Pharmaceuticals, Inc. | 8 months$20M as of Sep 30, 2026 | Feb 17, 2026max $20M | Jun 20, 2025S-3, $150M | +58% | None scheduled | Jun 3, 2026Underwritten, $20M | |
NRXP: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BMRABIOMERICA INC | 10 months$2.7M as of Aug 31, 2026 | May 10, 2024max $5.5Mfiled over 2 years ago | Sep 24, 2026S-3 | +60% | None scheduled | Aug 26, 2026Private placement | |
BMRA: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CLRBCellectar Biosciences, Inc. | 10 months$25M as of Sep 30, 2026 | May 24, 2024max $75Mfiled over 2 years ago | May 24, 2024S-3, $300M | +137% | None scheduled | May 8, 2026Private placement | |
CLRB: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| DBVTDBV Technologies S.A. | 10 months$166M as of Sep 30, 2026 | Sep 5, 2025max $150M | May 19, 2025S-3 | +86% | None scheduled | Mar 31, 2025Private placement | |
DBVT: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SERSerina Therapeutics, Inc. | 10 months$19M as of Sep 30, 2026 | Apr 28, 2025max $13M | Apr 2, 2025S-3, $100M | +149% | None scheduled | Aug 27, 2026Private placement | |
SER: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CRVOCervoMed Inc. | 10 months$20M as of Sep 30, 2026 | May 12, 2025max $50M | Oct 3, 2024S-3, $250M | +64% | None scheduled | Jun 22, 2026Private placement | |
CRVO: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ELTXElicio Therapeutics, Inc. | 10 months$31M as of Sep 30, 2026 | Mar 16, 2026max $100M | Feb 27, 2026S-3, $400M | +62% | None scheduled | Jul 2, 2026Direct / best efforts | |
ELTX: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| IVVDInvivyd, Inc. | 10 months$126M as of Jun 30, 2026 | Oct 2, 2025max $75M | Oct 2, 2025S-3, $350M | +145% | None scheduled | Nov 19, 2025Underwritten | |
IVVD: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CINGCingulate Inc. | 11 months$23M as of Jun 30, 2026 | Jan 12, 2026max $8.8M | Jan 12, 2026S-3, $200M | +169% | None scheduled | Feb 17, 2026Private placement | |
CING: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| INABIN8BIO, INC. | 11 months$14M as of Sep 30, 2026 | Jun 1, 2026max $2.8M | Nov 7, 2025S-3 | +133% | None scheduled | Dec 19, 2025Private placement | |
INAB: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| TNXPTonix Pharmaceuticals Holding Corp. | 12 months$163M as of Sep 30, 2026 | Nov 21, 2025size not stated | Jun 12, 2025S-3, $500M | +65% | None scheduled | Dec 29, 2025Direct / best efforts | |
TNXP: 90 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| MCRBSeres Therapeutics, Inc. | 3 months$18M as of Sep 30, 2026 | Aug 13, 2026max $100M | Aug 13, 2026S-3, $100M | +13% | None scheduled | Aug 4, 2026Underwritten | |
MCRB: 87 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ADXNAddex Therapeutics Ltd. | 4 months$0.8M as of Dec 31, 2025 | Dec 10, 2025max $3.3M | Nov 19, 2025F-3, $150M | +15% | None scheduled | None in 3 years | |
ADXN: 87 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VTGNVistagen Therapeutics, Inc. | 5 months$20M as of Sep 30, 2026 | Jun 17, 2025max $350M | Feb 13, 2024S-3, $100M | +17% | None scheduled | None in 3 years | |
VTGN: 87 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CNTBConnect Biopharma Holdings Ltd | 5 months$24M as of Sep 30, 2026 | Jun 10, 2025max $150M | Jun 10, 2025F-3, $150M | +15% | None scheduled | Mar 30, 2026Private placement | |
CNTB: 87 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VRCAVerrica Pharmaceuticals Inc. | 4 months$11M as of Sep 30, 2026 | None on file | Mar 11, 2025S-3, $150M | +81% | None scheduled | Nov 24, 2025Private placement | |
VRCA: 85 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| APLMApollomics Inc. | 4 months$3.3M as of Dec 31, 2025 | May 24, 2024max $19Mfiled over 2 years ago | Apr 1, 2024F-3, $200M | +99% | None scheduled | None in 3 years | |
APLM: 85 points, High
|
|||||||
| AKTXAkari Therapeutics Plc | 5 months$5.7M as of Jun 30, 2026 | None on file | Jul 29, 2025S-3 | +139% | None scheduled | May 22, 2026Private placement | |
AKTX: 85 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CVMCEL SCI CORP | 5 months$6.5M as of Jun 30, 2026 | None on file | Jul 3, 2025S-3 | +156% | None scheduled | Jun 15, 2026Direct / best efforts | |
CVM: 85 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| LONALeonaBio, Inc. | 5 months$32M as of Sep 30, 2026 | None on file | Oct 21, 2024S-3 | +232% | None scheduled | Dec 18, 2025Private placement | |
LONA: 85 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| OSTXOS Therapies Inc | 0 months$0.4M as of Sep 30, 2026Offering filed Oct 19, 2026, after this date | Aug 21, 2026max $75M | Aug 8, 2025S-3, $18M | +49% | None scheduled | Oct 19, 2026Private placement | |
OSTX: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| RADXRadiopharm Theranostics Ltd | 1 months$4.1M as of Jun 30, 2026Offering filed Jul 27, 2026, after this date | Jul 23, 2026max $9.3M | Dec 16, 2025F-3, $22M | +50% | None scheduled | Jul 27, 2026Direct / best efforts | |
RADX: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PRMEPrime Medicine, Inc. | 5 months$61M as of Jun 30, 2026Offering filed Nov 12, 2026, after this date | Nov 7, 2025max $200M | Nov 7, 2025S-3ASR, $200M | +35% | None scheduled | Nov 12, 2026Underwritten, $125M | |
PRME: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| LEXXLexaria Bioscience Corp. | 6 months$3.6M as of May 31, 2026Offering filed Sep 9, 2026, after this date | Feb 5, 2025max $5.0M | Jan 22, 2025S-3, $50M | +27% | None scheduled | Sep 9, 2026Private placement | |
LEXX: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| DAREDare Bioscience, Inc. | 6 months$13M as of Sep 30, 2026 | May 10, 2024max $18Mfiled over 2 years ago | Mar 29, 2024S-3, $200M | +38% | None scheduled | Aug 17, 2026Direct / best efforts | |
DARE: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| TVRDTvardi Therapeutics, Inc. | 6 months$16M as of Sep 30, 2026 | Jul 17, 2026max $9.7M | May 1, 2026S-3, $13M | +42% | None scheduled | None in 3 years | |
TVRD: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CLNNClene Inc. | 8 months$9.9M as of Sep 30, 2026 | Oct 17, 2025max $25M | Mar 24, 2025S-3, $160M | +39% | None scheduled | Sep 16, 2026Direct / best efforts | |
CLNN: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CHRSCoherus Oncology, Inc. | 9 months$136M as of Sep 30, 2026 | Aug 28, 2026max $50M | Nov 13, 2025S-3, $150M | +28% | None scheduled | Feb 13, 2026Underwritten | |
CHRS: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| TOVXTheriva Biologics, Inc. | 9 months$8.5M as of Sep 30, 2026 | Oct 29, 2025max $2.9M | May 2, 2024S-3, $1.2M | +36% | None scheduled | Oct 17, 2025Private placement | |
TOVX: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ELDNEledon Pharmaceuticals, Inc. | 10 months$70M as of Sep 30, 2026 | May 1, 2026max $75M | May 1, 2026S-3, $500M | +41% | None scheduled | Jan 2, 2026Private placement | |
ELDN: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| HUMAHumacyte, Inc. | 11 months$65M as of Sep 30, 2026 | Dec 16, 2025max $60M | Sep 12, 2025S-3, $350M | +48% | None scheduled | Jun 11, 2026Underwritten | |
HUMA: 84 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PCSAProcessa Pharmaceuticals, Inc. | 0 months$0.2M as of Sep 30, 2026 | Jul 25, 2025size not stated | May 21, 2024S-3, $2.4M | -95%split likely, not scored | None scheduled | Jul 29, 2026Private placement | |
PCSA: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| TPSTTempest Therapeutics, Inc. | 1 months$0.8M as of Sep 30, 2026 | Feb 6, 2025max $15M | Jul 19, 2024S-3, $300M | +350%split likely, not scored | None scheduled | Sep 15, 2026Private placement | |
TPST: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| BYSIBeyondSpring Inc. | 1 months$0.6M as of Sep 30, 2026 | Sep 29, 2026max $12M | Jun 12, 2024F-3 | +3% | None scheduled | None in 3 years | |
BYSI: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ONCYONCOLYTICS BIOTECH INC | 1 months$2.4M as of Sep 30, 2026 | Apr 6, 2026max $75M | Apr 1, 2026S-3, $250M | n/a | None scheduled | None in 3 years | |
ONCY: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| AWHLAspira Women's Health Inc. | 1 months$0.5M as of Sep 30, 2026 | Jan 8, 2025size not stated | Apr 22, 2024S-3, $100M | +9% | None scheduled | Jun 9, 2026Private placement | |
AWHL: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VNRXVOLITIONRX LTD | 2 months$2.4M as of Sep 30, 2026 | Oct 14, 2025size not stated | Nov 8, 2024S-3, $100M | -71%split likely, not scored | None scheduled | Sep 25, 2026Private placement | |
VNRX: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| JSPRJasper Therapeutics, Inc. | 2 months$7.3M as of Sep 30, 2026 | Mar 26, 2025max $100M | Mar 19, 2025S-3, $100M | -96%split likely, not scored | None scheduled | Jul 17, 2026Private placement | |
JSPR: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| QUCYQuantum Cyber N.V. | 3 months$5.0M as of Sep 30, 2026 | Oct 9, 2026max $100M | Jun 4, 2026S-3 | n/a | None scheduled | Apr 28, 2026Private placement | |
QUCY: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| MBRXMoleculin Biotech, Inc. | 3 months$7.3M as of Sep 30, 2026 | Aug 21, 2026max $6.5M | Jun 7, 2024S-3 | -98%split likely, not scored | None scheduled | Aug 3, 2026Direct / best efforts | |
MBRX: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| AEONAEON Biopharma, Inc. | 3 months$3.4M as of Sep 30, 2026 | Jun 16, 2025max $50M | Feb 9, 2026S-3 | +611%split likely, not scored | None scheduled | Jul 15, 2026Underwritten | |
AEON: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| AZTRAzitra, Inc. | 4 months$3.8M as of Sep 30, 2026 | Sep 28, 2026max $3.5M | Jul 1, 2024S-3, $50M | -41% | None scheduled | Mar 23, 2026Private placement | |
AZTR: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CLDICalidi Biotherapeutics, Inc. | 4 months$4.2M as of Sep 30, 2026 | Feb 5, 2025size not stated | Jan 10, 2025S-3, $5.1M | -52%split likely, not scored | None scheduled | Sep 17, 2026Direct / best efforts, $1.2M | |
CLDI: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| PULMPulmatrix, Inc. | 4 months$1.4M as of Sep 30, 2026 | May 17, 2024max $95Mfiled over 2 years ago | May 17, 2024S-3, $2.6M | 0% | None scheduled | Mar 27, 2026Private placement | |
PULM: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SCNXScienture Holdings, Inc. | 5 months$4.7M as of Sep 30, 2026 | Nov 7, 2025max $200M | Aug 1, 2025S-3 | -96%split likely, not scored | None scheduled | Aug 15, 2025Direct / best efforts | |
SCNX: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| OGENORAGENICS INC | 5 months$3.9M as of Sep 30, 2026 | Oct 11, 2024max $10Mfiled over 2 years ago | Jan 22, 2026S-3, $100M | +8% | None scheduled | Jul 2, 2025Direct / best efforts, $17M | |
OGEN: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| AIMAIM ImmunoTech Inc. | 6 months$6.9M as of Sep 30, 2026 | May 19, 2026max $3.4M | Apr 1, 2025S-3, $100M | +1,299%split likely, not scored | None scheduled | Sep 14, 2026Private placement | |
AIM: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| DRMADermata Therapeutics, Inc. | 6 months$4.8M as of Sep 30, 2026 | Jan 27, 2026size not stated | Nov 24, 2025S-3, $100M | +380%split likely, not scored | None scheduled | Aug 17, 2026Private placement | |
DRMA: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| KPTIKaryopharm Therapeutics Inc. | 8 months$65M as of Jun 30, 2026Offering filed Sep 11, 2026, after this date | May 4, 2026max $100M | May 4, 2026S-3, $100M | +162% | None scheduled | Sep 11, 2026Private placement | |
KPTI: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ATRAAtara Biotherapeutics, Inc. | 14 months$9.9M as of Sep 30, 2026 | Nov 10, 2026max $100M | Nov 10, 2026S-3, $23M | +41% | Mar 31, 2027in 133 days | Feb 23, 2026Private placement | |
ATRA: 80 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| NRSNNeuroSense Therapeutics Ltd. | 0 months$0.2M as of Dec 31, 2025 | Jan 29, 2026max $6.5M | Jan 29, 2026F-3, $150M | +40% | None scheduled | Aug 16, 2024Direct / best efforts, $4.5M | |
NRSN: 79 points, High
|
|||||||
| IGCIGC Pharma, Inc. | 1 months$0.4M as of Sep 30, 2026 | Sep 19, 2025max $60M | Dec 29, 2023S-3 | +26% | None scheduled | Jul 6, 2026Private placement | |
IGC: 79 points, High
|
|||||||
| COCPCocrystal Pharma, Inc. | 3 months$2.2M as of Sep 30, 2026 | None on file | Apr 23, 2026S-3 | +40% | None scheduled | Aug 3, 2026Private placement | |
COCP: 79 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| NTHINEONC TECHNOLOGIES HOLDINGS, INC. | 4 months$6.2M as of Sep 30, 2026 | None on file | Apr 2, 2026S-3, $300M | +48% | None scheduled | Sep 10, 2026Direct / best efforts | |
NTHI: 79 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BHVNBiohaven Ltd. | 5 months$161M as of Sep 30, 2026 | May 4, 2026max $350M | May 4, 2026S-3ASR | +43% | None scheduled | Nov 12, 2025Underwritten | |
BHVN: 79 points, High
|
|||||||
| GALTGALECTIN THERAPEUTICS INC | 13 months$13M as of Sep 30, 2026 | Mar 31, 2026max $200M | Mar 31, 2026S-3, $33M | +57% | None scheduled | Aug 4, 2026Private placement | |
GALT: 78 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BFRGBullFrog AI Holdings, Inc. | 13 months$6.9M as of Sep 30, 2026 | Apr 1, 2026max $4.3M | Aug 7, 2024S-3 | +64% | None scheduled | Sep 16, 2025Private placement | |
BFRG: 78 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SPRBSPRUCE BIOSCIENCES, INC. | 15 months$88M as of Sep 30, 2026 | Apr 21, 2026max $75M | Oct 29, 2025S-3, $300M | +169% | None scheduled | Jan 8, 2026Private placement | |
SPRB: 78 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SCLXScilex Holding Co | 0 months$0.6M as of Jun 30, 2026Offering filed Jul 6, 2026, after this date | Jan 11, 2024max $170Mfiled over 2 years ago | Apr 16, 2026S-3, $500M | +22% | None scheduled | Jul 6, 2026Private placement | |
SCLX: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CDTCDT Equity Inc. | 2 months$0.7M as of Sep 30, 2026Offering filed Oct 27, 2026, after this date | Apr 2, 2026max $3.6M | Oct 24, 2024S-3, $3.6M | +17% | None scheduled | Oct 27, 2026Private placement | |
CDT: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| NMRANeumora Therapeutics, Inc. | 6 months$86M as of Sep 30, 2026 | Oct 1, 2024max $300Mfiled over 2 years ago | Oct 1, 2024S-3ASR, $300M | +13% | None scheduled | Nov 21, 2025Private placement | |
NMRA: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| GANXGain Therapeutics, Inc. | 9 months$12M as of Sep 30, 2026 | Nov 28, 2025max $50M | May 28, 2025S-3, $100M | +23% | None scheduled | Jul 17, 2025Private placement | |
GANX: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VERUVERU INC. | 10 months$24M as of Jun 30, 2026 | Jul 2, 2026max $22M | Apr 7, 2026S-3 | +16% | None scheduled | Oct 30, 2025Underwritten | |
VERU: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PHIOPhio Pharmaceuticals Corp. | 10 months$11M as of Sep 30, 2026 | Apr 8, 2026max $6.4M | May 20, 2024S-3 | +11% | None scheduled | Nov 6, 2025Private placement | |
PHIO: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SANASana Biotechnology, Inc. | 10 months$122M as of Sep 30, 2026 | Mar 3, 2026max $150M | Mar 3, 2026S-3ASR, $150M | +13% | None scheduled | Apr 13, 2026Direct / best efforts | |
SANA: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| LRMRLarimar Therapeutics, Inc. | 10 months$129M as of Sep 30, 2026 | Feb 26, 2026max $100M | May 9, 2024S-3, $100M | +22% | None scheduled | Feb 25, 2026Underwritten | |
LRMR: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ABOSAcumen Pharmaceuticals, Inc. | 11 months$79M as of Sep 30, 2026 | Nov 13, 2025max $50M | Oct 26, 2026S-3, $500M | +19% | None scheduled | Mar 16, 2026Private placement | |
ABOS: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CRDFCardiff Oncology, Inc. | 11 months$40M as of Sep 30, 2026 | Feb 27, 2025max $150M | Feb 27, 2025S-3, $150M | +16% | None scheduled | Jul 16, 2026Direct / best efforts | |
CRDF: 77 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| TCRTAlaunos Therapeutics, Inc. | 1 months$0.1M as of Sep 30, 2026Offering filed Oct 13, 2026, after this date | None on file | Aug 21, 2025S-3, $50M | +89% | None scheduled | Oct 13, 2026Private placement | |
TCRT: 75 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| NXTCNextCure, Inc. | 2 months$8.7M as of Sep 30, 2026 | None on file | None | +71% | None scheduled | Dec 19, 2025Underwritten, $22M | |
NXTC: 75 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| RKTORocket One Inc. | 6 months$6.0M as of Sep 30, 2026 | Jul 31, 2026size not stated | Nov 17, 2025S-3 | +61% | None scheduled | Apr 2, 2026Direct / best efforts | |
RKTO: 75 points, High
|
|||||||
| CYPHCYPHERPUNK TECHNOLOGIES INC. | 8 months$7.6M as of Sep 30, 2026 | Nov 12, 2025max $200M | Mar 18, 2024S-3, $200M | +163% | None scheduled | Aug 18, 2026Private placement | |
CYPH: 75 points, High
|
|||||||
| RDHLRedHill Biopharma Ltd. | 8 months$5.2M as of Dec 31, 2025 | Oct 13, 2026max $2.6M | Aug 9, 2024F-3, $50M | +295% | None scheduled | Jan 26, 2024Direct / best efforts | |
RDHL: 75 points, High
|
|||||||
| PDSBPDS Biotechnology Corp | 8 months$15M as of Sep 30, 2026 | Jun 15, 2026max $50M | Aug 29, 2025S-3, $20M | +114% | None scheduled | Sep 8, 2026Private placement | |
PDSB: 75 points, High
|
|||||||
| HYPDHYPERION DEFI, INC. | 9 months$6.6M as of Sep 30, 2026 | May 6, 2026size not stated | Nov 17, 2025S-3, $500M | +91% | None scheduled | Jan 5, 2026Private placement | |
HYPD: 75 points, High
|
|||||||
| PPBTPURPLE BIOTECH LTD. | 9 months$6.1M as of Dec 31, 2025 | Sep 19, 2025max $2.3M | May 20, 2026F-3 | +260% | None scheduled | Sep 5, 2025Direct / best efforts | |
PPBT: 75 points, High
|
|||||||
| KALAKALA BIO, Inc. | 10 months$7.2M as of Jun 30, 2026 | Jul 22, 2026max $250M | May 7, 2026S-3 | +176% | None scheduled | Mar 4, 2026Private placement | |
KALA: 75 points, High
|
|||||||
| CTXRCitius Pharmaceuticals, Inc. | 10 months$17M as of Jun 30, 2026 | None on file | Feb 23, 2024S-3, $250M | +61% | None scheduled | Apr 29, 2026Private placement | |
CTXR: 75 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CDIOCardio Diagnostics Holdings, Inc. | 12 months$5.6M as of Sep 30, 2026 | Feb 14, 2025max $9.5M | Feb 7, 2025S-3, $9.5M | +62% | None scheduled | Feb 2, 2024Private placement | |
CDIO: 75 points, High
|
|||||||
| HURATuHURA Biosciences, Inc./NV | 1 months$1.9M as of Sep 30, 2026 | Apr 8, 2026max $50M | Nov 3, 2025S-3, $50M | +28% | None scheduled | Aug 19, 2026Private placement | |
HURA: 74 points, High
|
|||||||
| BIVIBIOVIE INC. | 7 months$7.7M as of Sep 30, 2026Offering filed Nov 6, 2026, after this date | Nov 5, 2026max $1.2M | Jun 18, 2026S-3, $300M | +42% | None scheduled | Nov 6, 2026Private placement | |
BIVI: 74 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| BTTCBlack Titan Corp | 7 months$2.9M as of Jul 31, 2026 | None on file | None | +94% | None scheduled | None in 3 years | |
BTTC: 73 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ESLAEstrella Immunopharma, Inc. | 0 months$0.1M as of Sep 30, 2026 | None on file | Dec 12, 2024S-3, $100M | +16% | None scheduled | Jan 6, 2026Direct / best efforts | |
ESLA: 72 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| IPHAInnate Pharma SA | 3 months$11M as of Dec 31, 2025 | Feb 6, 2024max $75Mfiled over 2 years ago | Dec 20, 2023F-3, $200M | +12% | None scheduled | None in 3 years | |
IPHA: 72 points, High
|
|||||||
| ACRVAcrivon Therapeutics, Inc. | 15 months$90M as of Sep 30, 2026 | Dec 1, 2023max $100Mfiled over 2 years ago | Nov 16, 2026S-3, $300M | +36% | None scheduled | Apr 9, 2024Private placement | |
ACRV: 72 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SXTP60 DEGREES PHARMACEUTICALS, INC. | 0 months$0.3M as of Sep 30, 2026Offering filed Nov 6, 2026, after this date | Mar 13, 2026size not stated | Jul 12, 2024S-3, $15M | +6% | None scheduled | Nov 6, 2026Private placement | |
SXTP: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| HLSQTessera Defense & Homeland Security Inc. | 1 months$0.6M as of Jun 30, 2026Offering filed Oct 23, 2026, after this date | Jul 27, 2026max $9.1M | Dec 7, 2023S-3, $7.5M | +1% | None scheduled | Oct 23, 2026Private placement | |
HLSQ: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| FBLGFibroBiologics, Inc. | 1 months$1.2M as of Sep 30, 2026Offering filed Oct 8, 2026, after this date | May 6, 2026max $7.5M | Feb 3, 2025S-3, $50M | -83%split likely, not scored | None scheduled | Oct 8, 2026Private placement | |
FBLG: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CRISCURIS INC | 2 months$5.1M as of Sep 30, 2026Offering filed Oct 19, 2026, after this date | Feb 8, 2024max $300Mfiled over 2 years ago | Feb 8, 2024S-3, $300M | -26% | None scheduled | Oct 19, 2026Private placement | |
CRIS: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| NCELNewcelX Ltd. | 2 months$0.7M as of Dec 31, 2025 | None on file | Feb 10, 2025F-3 | +52% | None scheduled | Jul 1, 2024Direct / best efforts | |
NCEL: 70 points, High
|
|||||||
| OTLKOutlook Therapeutics, Inc. | 2 months$11M as of Jun 30, 2026Offering filed Aug 14, 2026, after this date | Apr 12, 2024max $100Mfiled over 2 years ago | Mar 28, 2024S-3, $300M | +448%split likely, not scored | None scheduled | Aug 14, 2026Direct / best efforts, $15M | |
OTLK: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MEDSDataMeds AI, Inc. | 2 months$2.5M as of Sep 30, 2026Offering filed Oct 16, 2026, after this date | Nov 16, 2026max $10M | Apr 15, 2026S-3, $3.1M | -94%split likely, not scored | None scheduled | Oct 16, 2026Private placement | |
MEDS: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| TLSATiziana Life Sciences Ltd | 3 months$3.2M as of Dec 31, 2025Offering filed Jan 22, 2026, after this date | Mar 24, 2025max $100M | Mar 24, 2025F-3, $250M | +8% | None scheduled | Jan 22, 2026Direct / best efforts, $8.8M | |
TLSA: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ICUSeaStar Medical Holding Corp | 4 months$4.0M as of Sep 30, 2026Offering filed Oct 5, 2026, after this date | Nov 20, 2025max $2.3M | Dec 8, 2023S-3, $100M | -85%split likely, not scored | None scheduled | Oct 5, 2026Private placement | |
ICU: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| APVOAptevo Therapeutics Inc. | 4 months$9.8M as of Sep 30, 2026Offering filed Nov 12, 2026, after this date | Oct 30, 2026max $50M | Feb 14, 2025S-3, $100M | -79%split likely, not scored | None scheduled | Nov 12, 2026Private placement | |
APVO: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| SLXNSilexion Therapeutics Corp | 7 months$4.8M as of Sep 30, 2026 | Sep 26, 2025max $13M | Jun 12, 2026S-3, $13M | -79%split likely, not scored | None scheduled | Sep 29, 2026Private placement | |
SLXN: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| GLSIGreenwich LifeSciences, Inc. | 7 months$5.9M as of Sep 30, 2026 | Oct 7, 2024max $100Mfiled over 2 years ago | Oct 7, 2024S-3, $100M | +6% | None scheduled | Jun 17, 2024Private placement | |
GLSI: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ARMPArmata Pharmaceuticals, Inc. | 8 months$18M as of Jun 30, 2026 | Dec 1, 2025max $100M | Aug 13, 2025S-3, $100M | +3% | None scheduled | None in 3 years | |
ARMP: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| KAPAKairos Pharma, LTD. | 8 months$2.6M as of Sep 30, 2026 | Jan 13, 2026max $4.5M | Jan 13, 2026S-3, $4.5M | -78%split likely, not scored | None scheduled | Jan 17, 2025Private placement | |
KAPA: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ATOSATOSSA THERAPEUTICS, INC. | 8 months$21M as of Sep 30, 2026 | Feb 20, 2026max $50M | May 13, 2024S-3 | -92%split likely, not scored | None scheduled | Jun 12, 2026Direct / best efforts | |
ATOS: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| VIVSVivoSim Labs, INC. | 9 months$8.6M as of Sep 30, 2026 | Apr 11, 2025max $5.3M | Jan 26, 2024S-3, $2.6M | +678%split likely, not scored | None scheduled | Jul 17, 2026Private placement | |
VIVS: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| PASGPassage BIO, Inc. | 9 months$20M as of Sep 30, 2026 | Mar 5, 2025max $125M | Mar 4, 2024S-3, $50M | +1% | None scheduled | Sep 3, 2026Private placement | |
PASG: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| DCOYDecoy Therapeutics Inc. | 9 months$8.2M as of Sep 30, 2026 | Aug 22, 2025max $2.6M | Nov 13, 2026S-3 | -59%split likely, not scored | None scheduled | Sep 23, 2026Private placement | |
DCOY: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| MTVAMetaVia Inc. | 10 months$13M as of Sep 30, 2026 | Jul 2, 2026max $2.3M | Apr 12, 2024S-3, $150M | -72%split likely, not scored | None scheduled | Jan 16, 2026Underwritten | |
MTVA: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| CALCCalciMedica, Inc. | 10 months$14M as of Sep 30, 2026 | Nov 6, 2025max $9.7M | Mar 3, 2026S-3 | n/a | None scheduled | Sep 30, 2026Underwritten, $25M | |
CALC: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| AZRAzora Therapeutics, Inc. (DE) | 10 months$22M as of Sep 30, 2026 | Nov 17, 2026max $20M | Nov 17, 2026S-3, $250M | -40% | None scheduled | Aug 25, 2026Private placement | |
AZR: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ADILAzora Therapeutics, Inc. (DE) | 10 months$22M as of Sep 30, 2026 | Nov 17, 2026max $20M | Nov 17, 2026S-3, $250M | -40% | None scheduled | Aug 25, 2026Private placement | |
ADIL: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| INTSINTENSITY THERAPEUTICS, INC. | 11 months$8.5M as of Sep 30, 2026 | Mar 23, 2026max $15M | Jul 3, 2024S-3, $15M | -95%split likely, not scored | None scheduled | Nov 3, 2025Direct / best efforts, $4.0M | |
INTS: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ENVBEnveric Biosciences, Inc. | 11 months$8.3M as of Sep 30, 2026 | Jun 9, 2026max $2.4M | Jul 8, 2024S-3 | +650%split likely, not scored | None scheduled | Apr 20, 2026Private placement | |
ENVB: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| LGVNLongeveron Inc. | 11 months$18M as of Sep 30, 2026 | Sep 19, 2025max $11M | Mar 28, 2025S-3, $70M | n/a | None scheduled | Mar 12, 2026Private placement | |
LGVN: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| GNPXGenprex, Inc. | 11 months$15M as of Sep 30, 2026 | Nov 21, 2025size not stated | Jun 5, 2026S-3, $250M | -41% | None scheduled | Oct 29, 2025Direct / best efforts, $3.4M | |
GNPX: 70 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| NNVCNANOVIRICIDES, INC. | 3 months$2.6M as of Jun 30, 2026Offering filed Jul 27, 2026, after this date | Oct 21, 2026max $2.4M | Jun 5, 2026S-3 | +46% | None scheduled | Jul 27, 2026Direct / best efforts | |
NNVC: 69 points, High
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| RNXTRenovoRx, Inc. | 12 months$10M as of Sep 30, 2026 | Nov 14, 2025max $3.7M | Nov 14, 2025S-3, $50M | +32% | None scheduled | Mar 23, 2026Private placement | |
RNXT: 69 points, High
|
|||||||
| TELOTelomir Pharmaceuticals, Inc. | 17 months$4.5M as of Sep 30, 2026Offering filed Oct 6, 2026, after this date | Feb 14, 2025max $150M | Feb 14, 2025S-3, $100M | +114% | None scheduled | Oct 6, 2026Private placement | |
TELO: 68 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| SNGXSOLIGENIX, INC. | 17 months$9.0M as of Sep 30, 2026 | Jun 26, 2026max $6.4M | None | +132% | None scheduled | Sep 26, 2025Direct / best efforts, $1.4M | |
SNGX: 68 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ELABPMGC Holdings Inc. | 23 months$19M as of Sep 30, 2026 | Nov 22, 2023size not statedfiled over 2 years ago | Jan 27, 2025S-3 | +57% | None scheduled | Apr 20, 2026Direct / best efforts | |
ELAB: 68 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| LTRNLantern Pharma Inc. | 7 months$7.4M as of Jun 30, 2026Offering filed Sep 30, 2026, after this date | Jul 3, 2025max $16M | May 24, 2024S-3, $150M | +18% | None scheduled | Sep 30, 2026Direct / best efforts | |
LTRN: 67 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| DYAIDYADIC INTERNATIONAL INC | 8 months$4.6M as of Sep 30, 2026 | Mar 6, 2026max $4.2M | None | +11% | None scheduled | Aug 14, 2026Private placement | |
DYAI: 67 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| GOVXGeoVax Labs, Inc. | 2 months$2.2M as of Sep 30, 2026 | Jan 26, 2026max $30M | Mar 1, 2024S-3, $100M | -98%split likely, not scored | None scheduled | Aug 28, 2026Private placement | |
GOVX: 65 points, High
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| GRDXGridAI Technologies Corp. | 3 months$1.4M as of Sep 30, 2026Offering filed Oct 28, 2026, after this date | None on file | None | +205% | None scheduled | Oct 28, 2026Private placement | |
GRDX: 65 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| JUNSJUPITER NEUROSCIENCES, INC. | 3 months$1.5M as of Sep 30, 2026 | None on file | Apr 16, 2026S-3, $100M | -96%split likely, not scored | None scheduled | Aug 24, 2026Direct / best efforts | |
JUNS: 65 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ORGOOrganogenesis Holdings Inc. | 3 months$21M as of Sep 30, 2026 | Aug 6, 2026max $75M | Aug 8, 2024S-3, $250M | +2% | None scheduled | Nov 13, 2024Private placement | |
ORGO: 65 points, High
|
|||||||
| CUECue Biopharma, Inc. | 3 months$17M as of Sep 30, 2026 | Mar 16, 2026max $13M | Mar 16, 2026S-3, $300M | -89%split likely, not scored | None scheduled | Jul 10, 2026Private placement | |
CUE: 65 points, High
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| SKYESkye Bioscience, Inc. | 4 months$10M as of Sep 30, 2026 | May 10, 2024max $100Mfiled over 2 years ago | May 10, 2024S-3, $300M | -86%split likely, not scored | None scheduled | Aug 24, 2026Private placement | |
SKYE: 65 points, High
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ENLVEnlivex Ltd. | 4 months$5.5M as of Dec 31, 2025 | Nov 24, 2025max $300M | May 2, 2025F-3 | +904%split likely, not scored | None scheduled | May 29, 2024Direct / best efforts | |
ENLV: 65 points, High
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| GOSSGossamer Bio, Inc. | 5 months$51M as of Sep 30, 2026 | None on file | Jan 28, 2026S-3ASR | -97%split likely, not scored | None scheduled | Aug 21, 2026Private placement | |
GOSS: 65 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ERNAErnexa Therapeutics Inc. | 5 months$5.6M as of Sep 30, 2026 | Mar 16, 2026max $9.2M | Mar 16, 2026S-3, $9.2M | -78%split likely, not scored | None scheduled | Feb 10, 2026Direct / best efforts | |
ERNA: 65 points, High
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| GDTCCytoMed Therapeutics Ltd | 5 months$1.5M as of Dec 31, 2025 | Aug 18, 2025size not stated | Jun 13, 2025F-3 | +3% | None scheduled | None in 3 years | |
GDTC: 65 points, High
|
|||||||
| RNAZTranscode Therapeutics, Inc. | 5 months$8.4M as of Sep 30, 2026 | None on file | Dec 12, 2025S-3, $150M | +1,787%split likely, not scored | None scheduled | Apr 7, 2026Private placement | |
RNAZ: 65 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| CMMBChemomab Therapeutics Ltd. | 10 months$21M as of Dec 31, 2025 | Jul 25, 2025max $7.3M | None | +53% | None scheduled | None in 3 years | |
CMMB: 65 points, High
|
|||||||
| COYACoya Therapeutics, Inc. | 15 months$36M as of Sep 30, 2026 | May 12, 2026max $30M | Aug 12, 2025S-3, $75M | +12% | None scheduled | Jan 30, 2026Private placement | |
COYA: 65 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PPCBPropanc Biopharma, Inc. | 0 months$0.3M as of Sep 30, 2026 | None on file | None | -92%split likely, not scored | None scheduled | Nov 10, 2025Private placement | |
PPCB: 63 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ONMDOneMedNet Corp | 1 months$0.4M as of Sep 30, 2026 | None on file | None | -88%split likely, not scored | None scheduled | Jun 24, 2025Private placement | |
ONMD: 63 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| LIMNLiminatus Pharma, Inc. | 6 months$3.0M as of Jun 30, 2026Offering filed Nov 3, 2026, after this date | None on file | None | +148% | None scheduled | Nov 3, 2026Private placement | |
LIMN: 63 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ACXPAcurx Pharmaceuticals, Inc. | 14 months$9.7M as of Jun 30, 2026 | None on file | Jul 9, 2025S-3, $50M | +233% | None scheduled | Apr 16, 2026Direct / best efforts | |
ACXP: 63 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CNSPCNS Pharmaceuticals, Inc. | 14 months$17M as of Sep 30, 2026 | Sep 19, 2025max $44M | May 9, 2024S-3 | +138% | None scheduled | May 4, 2026Private placement | |
CNSP: 63 points, High
|
|||||||
| HCWBHCW Biologics Inc. | 1 months$1.0M as of Sep 30, 2026 | None on file | None | +16% | None scheduled | Sep 24, 2026Private placement | |
HCWB: 62 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| IMDXInsight Molecular Diagnostics Inc. | 4 months$11M as of Sep 30, 2026Offering filed Nov 16, 2026, after this date | None on file | Aug 1, 2024S-3, $100M | +14% | None scheduled | Nov 16, 2026Underwritten | |
IMDX: 62 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| EXOZEXOZYMES INC. | 11 months$5.7M as of Sep 30, 2026 | None on file | Jan 16, 2026S-3 | +13% | None scheduled | Jun 30, 2026Direct / best efforts | |
EXOZ: 62 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VERAVera Therapeutics, Inc. | 12 months$384M as of Sep 30, 2026 | Aug 5, 2025max $200M | Oct 28, 2024S-3ASR | +13% | None scheduled | Dec 10, 2025Underwritten, $261M | |
VERA: 62 points, High
|
|||||||
| ZNTLZentalis Pharmaceuticals, Inc. | 20 months$229M as of Sep 30, 2026 | Mar 26, 2025max $75M | Mar 26, 2025S-3, $75M | +36% | None scheduled | Aug 14, 2026Underwritten, $81M | |
ZNTL: 62 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PMVPPMV Pharmaceuticals, Inc. | 20 months$109M as of Sep 30, 2026 | Nov 20, 2024max $200M | Nov 20, 2024S-3, $114M | +42% | None scheduled | Sep 2, 2026Underwritten | |
PMVP: 62 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BIAFbioAffinity Technologies, Inc. | 2 months$2.6M as of Sep 30, 2026Offering filed Oct 9, 2026, after this date | Nov 3, 2026size not stated | None | -60%split likely, not scored | None scheduled | Oct 9, 2026Direct / best efforts | |
BIAF: 60 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PTNPALATIN TECHNOLOGIES INC | 6 months$7.5M as of Sep 30, 2026 | Feb 12, 2025max $6.0M | None | +5% | None scheduled | Nov 12, 2025Underwritten | |
PTN: 60 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ZSTKZeroStack Corp. | 6 months$2.6M as of Jun 30, 2026Offering filed Aug 19, 2026, after this date | Sep 29, 2025max $3.5M | Aug 26, 2026S-3 | -23% | None scheduled | Aug 19, 2026Private placement | |
ZSTK: 60 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PYXSPyxis Oncology, Inc. | 10 months$56M as of Sep 30, 2026Offering filed Oct 1, 2026, after this date | Sep 29, 2026max $150M | Nov 26, 2025S-3, $350M | +92% | None scheduled | Oct 1, 2026Underwritten | |
PYXS: 60 points, High
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| EOCNEoCene Ltd. | 11 months$8.8M as of Jun 30, 2026 | None on file | Nov 14, 2024F-3, $200M | +298% | None scheduled | None in 3 years | |
EOCN: 60 points, High
|
|||||||
| INOINOVIO PHARMACEUTICALS, INC. | 25 months$140M pro forma for events after Sep 30, 2026 | Aug 13, 2024max $60Mfiled over 2 years ago | Jul 2, 2026S-3, $300M | +250% | None scheduled | Nov 6, 2026Underwritten | |
INO: 60 points, High
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| AGENAGENUS INC | 10 months$87M as of Sep 30, 2026 | Aug 8, 2024size not statedfiled over 2 years ago | None | +33% | None scheduled | Aug 18, 2026Private placement | |
AGEN: 59 points, Elevated
|
|||||||
| GRIGRI Bio, Inc. | 13 months$11M as of Sep 30, 2026 | Jan 30, 2026max $60M | Jan 30, 2026S-3, $250M | -33% | None scheduled | Dec 12, 2025Direct / best efforts | |
GRI: 58 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| MRKRMarker Therapeutics, Inc. | 13 months$11M as of Sep 30, 2026 | Nov 27, 2024max $11M | Nov 27, 2024S-3, $300M | 0% | None scheduled | Dec 23, 2024Private placement | |
MRKR: 58 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CNTXContext Therapeutics Inc. | 15 months$34M as of Sep 30, 2026 | Oct 24, 2025max $75M | Nov 6, 2024S-3, $250M | 0% | None scheduled | May 2, 2024Private placement | |
CNTX: 58 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ACETAdicet Bio, Inc. | 16 months$101M as of Sep 30, 2026 | Mar 18, 2025max $100M | Mar 12, 2026S-3, $250M | -94%split likely, not scored | None scheduled | Apr 28, 2026Private placement | |
ACET: 58 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| MIRAMIRA PHARMACEUTICALS, INC. | 17 months$7.0M as of Sep 30, 2026 | Dec 5, 2025max $15M | Aug 12, 2024S-3, $19M | +0% | None scheduled | Sep 30, 2025Private placement | |
MIRA: 58 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VRAXVirax Biolabs Group Ltd | 17 months$6.5M as of Mar 31, 2026 | Sep 4, 2026max $2.1M | Dec 5, 2023F-3 | -87%split likely, not scored | None scheduled | Aug 23, 2024Direct / best efforts | |
VRAX: 58 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| KYTXKyverna Therapeutics, Inc. | 14 months$171M as of Sep 30, 2026 | Apr 2, 2026max $100M | Mar 26, 2026S-3, $100M | +44% | None scheduled | Dec 18, 2025Underwritten, $100M | |
KYTX: 57 points, Elevated
|
|||||||
| FBIOPFortress Biotech, Inc. | 14 months$152M as of Sep 30, 2026 | Sep 20, 2024max $13Mfiled over 2 years ago | May 17, 2024S-3, $50M | +26% | None scheduled | Dec 15, 2025Private placement | |
FBIOP: 57 points, Elevated
|
|||||||
| FBIOFortress Biotech, Inc. | 14 months$152M as of Sep 30, 2026 | Sep 20, 2024max $13Mfiled over 2 years ago | May 17, 2024S-3, $50M | +26% | None scheduled | Dec 15, 2025Private placement | |
FBIO: 57 points, Elevated
|
|||||||
| CAPRCAPRICOR THERAPEUTICS, INC. | 18 months$198M as of Sep 30, 2026 | Sep 10, 2025max $150M | Sep 10, 2025S-3, $300M | +27% | None scheduled | Dec 5, 2025Underwritten | |
CAPR: 57 points, Elevated
|
|||||||
| FDMT4D Molecular Therapeutics, Inc. | 18 months$375M as of Jun 30, 2026 | Jun 7, 2024max $250Mfiled over 2 years ago | May 7, 2026S-3, $400M | +50% | None scheduled | Jan 26, 2026Private placement | |
FDMT: 57 points, Elevated
|
|||||||
| DYNDyne Therapeutics, Inc. | 22 months$1.13B as of Sep 30, 2026 | Nov 12, 2024max $300Mfiled over 2 years ago | Mar 5, 2024S-3ASR, $200M | +31% | Jan 21, 2027in 64 days | Jul 22, 2026Underwritten, $375M | |
DYN: 57 points, Elevated
|
|||||||
| APUSApimeds Pharmaceuticals US, Inc. | 0 months$0.0M as of Sep 30, 2026 | None on file | None | -85%split likely, not scored | None scheduled | Dec 2, 2025Private placement | |
APUS: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| XTLBXTL BIOPHARMACEUTICALS LTD | 1 months$0.1M as of Dec 31, 2025 | None on file | None | +7% | None scheduled | None in 3 years | |
XTLB: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| TVGNTevogen Inc. | 1 months$1.1M as of Sep 30, 2026Offering filed Nov 3, 2026, after this date | Jul 3, 2025max $50M | Jun 20, 2025S-3, $150M | -65%split likely, not scored | None scheduled | Nov 3, 2026Private placement | |
TVGN: 55 points, Elevated
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MDCXMedicus Pharma Ltd. | 1 months$5.0M as of Sep 30, 2026Offering filed Nov 16, 2026, after this date | Jan 2, 2026max $15M | Dec 30, 2025S-3, $100M | -91%split likely, not scored | None scheduled | Nov 16, 2026Private placement | |
MDCX: 55 points, Elevated
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| TXMDTherapeuticsMD, Inc. | 2 months$10M as of Sep 30, 2026 | None on file | None | 0% | None scheduled | None in 3 years | |
TXMD: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| DWTXDogwood Therapeutics, Inc. | 4 months$4.9M as of Sep 30, 2026Offering filed Oct 19, 2026, after this date | Nov 28, 2025max $8.6M | May 23, 2025S-3, $150M | +1,567%split likely, not scored | None scheduled | Oct 19, 2026Private placement | |
DWTX: 55 points, Elevated
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MENSJyong Biotech Ltd. | 5 months$1.2M as of Dec 31, 2025 | None on file | None | n/a | None scheduled | Jun 18, 2025Underwritten | |
MENS: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| XCUREXICURE, INC. | 5 months$1.7M as of Jun 30, 2026 | None on file | None | +4% | None scheduled | Feb 21, 2025Private placement | |
XCUR: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SDEVStablecoin Development Corp | 6 months$7.2M as of Sep 30, 2026 | Jan 20, 2026max $100M | Oct 3, 2025S-3, $200M | -42% | None scheduled | Jan 16, 2026Private placement | |
SDEV: 55 points, Elevated
|
|||||||
| ALGSAligos Therapeutics, Inc. | 8 months$31M as of Sep 30, 2026 | None on file | Nov 6, 2024S-3, $400M | n/a | None scheduled | Feb 12, 2025Private placement | |
ALGS: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| TCRXTScan Therapeutics, Inc. | 8 months$73M as of Sep 30, 2026 | None on file | Mar 5, 2025S-3, $300M | n/a | None scheduled | Dec 26, 2024Direct / best efforts | |
TCRX: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| QNTMQuantum Biopharma Ltd. | 8 months$3.9M as of Dec 31, 2025 | Dec 22, 2025size not stated | Dec 26, 2023F-3 | -83%split likely, not scored | None scheduled | None in 3 years | |
QNTM: 55 points, Elevated
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| RFLRafael Holdings, Inc. | 9 months$22M as of Jul 31, 2026 | None on file | Apr 18, 2025S-3, $25M | n/a | None scheduled | Jun 4, 2025Private placement | |
RFL: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BMEABiomea Fusion, Inc. | 9 months$26M as of Sep 30, 2026 | None on file | Aug 5, 2025S-3, $100M | +3% | None scheduled | Sep 22, 2026Underwritten | |
BMEA: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SPRYARS Pharmaceuticals, Inc. | 9 months$138M as of Sep 30, 2026 | Jan 31, 2025max $200M | Jan 31, 2025S-3ASR, $200M | +2% | None scheduled | None in 3 years | |
SPRY: 55 points, Elevated
|
|||||||
| CANFCan-Fite BioPharma Ltd. | 9 months$7.0M as of Dec 31, 2025 | May 9, 2025max $2.6M | Aug 28, 2026F-3, $100M | -100%split likely, not scored | None scheduled | Jul 29, 2025Direct / best efforts | |
CANF: 55 points, Elevated
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| BCTXBriaCell Therapeutics Corp. | 10 months$21M as of Jul 31, 2026 | None on file | Jan 22, 2024S-3, $200M | +364%split likely, not scored | None scheduled | Jun 3, 2026Private placement | |
BCTX: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| TRIBTRINITY BIOTECH PLC | 10 months$5.1M as of Dec 31, 2025 | Jun 12, 2026max $4.4M | Jun 21, 2024F-3 | +4% | None scheduled | None in 3 years | |
TRIB: 55 points, Elevated
|
|||||||
| ELUTELUTIA INC. | 11 months$29M as of Sep 30, 2026 | May 8, 2025size not stated | Mar 18, 2025S-3, $50M | n/a | None scheduled | May 8, 2025Private placement | |
ELUT: 55 points, Elevated
|
|||||||
| ZYMEZymeworks Inc. | 11 months$100M as of Sep 30, 2026 | Aug 2, 2024max $150Mfiled over 2 years ago | May 2, 2024S-3ASR | -8% | None scheduled | Aug 11, 2025Private placement | |
ZYME: 55 points, Elevated
|
|||||||
| SVRASavara Inc | 11 months$130M as of Sep 30, 2026 | Jun 28, 2024max $100Mfiled over 2 years ago | May 9, 2024S-3, $400M | +8% | None scheduled | Oct 30, 2025Underwritten | |
SVRA: 55 points, Elevated
|
|||||||
| MNKDMANNKIND CORP | 11 months$97M as of Sep 30, 2026 | Feb 26, 2025max $200M | Feb 26, 2025S-3ASR, $200M | +5% | None scheduled | Jul 24, 2026Private placement | |
MNKD: 55 points, Elevated
|
|||||||
| REVBREVELATION BIOSCIENCES, INC. | 11 months$9.1M as of Sep 30, 2026 | None on file | Jul 19, 2024S-3 | -89%split likely, not scored | None scheduled | Jan 29, 2026Private placement | |
REVB: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| URGNUroGen Pharma Ltd. | 11 months$92M as of Sep 30, 2026 | Nov 6, 2025max $75M | Nov 6, 2025S-3ASR, $75M | +5% | Jun 14, 2027in 208 days | Feb 20, 2025Private placement | |
URGN: 55 points, Elevated
|
|||||||
| BOLDBoundless Bio, Inc. | 12 months$63M as of Sep 30, 2026 | Apr 1, 2025max $15M | Apr 1, 2025S-3, $15M | +6% | None scheduled | Jun 23, 2026Private placement | |
BOLD: 55 points, Elevated
|
|||||||
| INMBInmune Bio, Inc. | 15 months$16M as of Sep 30, 2026Offering filed Oct 29, 2026, after this date | Dec 19, 2025max $250M | May 1, 2024S-3, $250M | +17% | None scheduled | Oct 29, 2026Direct / best efforts | |
INMB: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| LSTALISATA THERAPEUTICS, INC. | 20 months$19M as of Sep 30, 2026 | Aug 21, 2024size not statedfiled over 2 years ago | May 1, 2024S-3, $150M | +23% | None scheduled | Sep 17, 2026Private placement | |
LSTA: 55 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| OLMAOlema Oncology, Inc. | 27 months$414M as of Sep 30, 2026 | Dec 11, 2025max $200M | Dec 11, 2025S-3ASR, $200M | +28% | None scheduled | Jan 10, 2025Private placement | |
OLMA: 54 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| RGNXREGENXBIO Inc. | 74 months$290M pro forma for events after Sep 30, 2026 | Feb 12, 2026max $150M | Nov 26, 2025S-3, $300M | +31% | None scheduled | Jul 17, 2026Underwritten | |
RGNX: 54 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SHPHShuttle Pharmaceuticals Holdings, Inc. | 0 months$0.1M as of Jun 30, 2026Offering filed Sep 16, 2026, after this date | None on file | None | +345%split likely, not scored | None scheduled | Sep 16, 2026Private placement | |
SHPH: 53 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| LABTLakewood-Amedex Biotherapeutics Inc. | 11 months$4.6M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Apr 23, 2026Underwritten, $7.5M | |
LABT: 53 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VSTMVerastem, Inc. | 13 months$173M as of Sep 30, 2026Offering filed Oct 14, 2026, after this date | Nov 5, 2026max $100M | Nov 5, 2026S-3ASR, $100M | +89% | None scheduled | Oct 14, 2026Underwritten | |
VSTM: 53 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CNTNCanton Strategic Holdings, Inc. | 20 months$27M as of Sep 30, 2026 | Mar 3, 2026max $300M | Jan 9, 2026S-3, $65M | +133% | None scheduled | Jan 20, 2026Underwritten, $545M | |
CNTN: 53 points, Elevated
|
|||||||
| KODKodiak Sciences Inc. | 9 months$126M as of Sep 30, 2026 | None on file | None | +23% | None scheduled | Dec 17, 2025Underwritten, $160M | |
KOD: 52 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| MTNBMatinas BioPharma Holdings, Inc. | 1 months$0.8M as of Sep 30, 2026 | None on file | Jun 16, 2026S-3, $150M | -83%split likely, not scored | None scheduled | Jul 13, 2026Private placement | |
MTNB: 50 points, Elevated
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| BFRIBiofrontera Inc. | 6 months$3.2M as of Sep 30, 2026 | None on file | None | +54% | None scheduled | Oct 24, 2025Private placement | |
BFRI: 50 points, Elevated
|
|||||||
| AARDAardvark Therapeutics, Inc. | 12 months$60M as of Sep 30, 2026 | Apr 3, 2026max $150M | Mar 23, 2026S-3, $150M | +1% | None scheduled | Feb 13, 2025Underwritten | |
AARD: 50 points, Elevated
|
|||||||
| KYNBKYNTRA BIO, INC. | 12 months$40M as of Sep 30, 2026 | Feb 24, 2025max $30M | Jun 28, 2024S-3 | +0% | None scheduled | None in 3 years | |
KYNB: 50 points, Elevated
|
|||||||
| TLPHTALPHERA, INC. | 12 months$14M as of Sep 30, 2026 | None on file | Nov 12, 2026S-3 | +12% | None scheduled | Mar 16, 2026Private placement | |
TLPH: 50 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CRBUCaribou Biosciences, Inc. | 13 months$95M as of Sep 30, 2026 | May 8, 2025max $100M | May 8, 2025S-3, $300M | +16% | None scheduled | None in 3 years | |
CRBU: 50 points, Elevated
|
|||||||
| CRBPCorbus Pharmaceuticals Holdings, Inc. | 14 months$115M as of Sep 30, 2026 | Aug 7, 2026max $128M | Mar 11, 2026S-3, $300M | +17% | None scheduled | None in 3 years | |
CRBP: 50 points, Elevated
|
|||||||
| REPLReplimune Group, Inc. | 15 months$308M as of Sep 30, 2026 | May 23, 2025max $100M | Aug 14, 2026S-3ASR | +21% | None scheduled | Aug 10, 2026Underwritten | |
REPL: 50 points, Elevated
|
|||||||
| RNACCartesian Therapeutics, Inc. | 15 months$123M as of Sep 30, 2026 | Dec 13, 2024max $100M | Dec 13, 2024S-3, $400M | +17% | None scheduled | May 26, 2026Private placement | |
RNAC: 50 points, Elevated
|
|||||||
| CTORCITIUS ONCOLOGY, INC. | 15 months$17M as of Jun 30, 2026 | None on file | Sep 2, 2025S-3, $200M | +19% | None scheduled | May 6, 2026Private placement | |
CTOR: 50 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| GYREGYRE THERAPEUTICS, INC. | 17 months$57M as of Sep 30, 2026 | Nov 27, 2024max $50M | Nov 14, 2024S-3, $150M | +20% | None scheduled | May 4, 2026Private placement | |
GYRE: 50 points, Elevated
|
|||||||
| STOKStoke Therapeutics, Inc. | 18 months$359M as of Sep 30, 2026 | Aug 3, 2026max $200M | Mar 18, 2026S-3ASR, $150M | +15% | None scheduled | Mar 28, 2024Underwritten | |
STOK: 50 points, Elevated
|
|||||||
| BOLTBolt Biotherapeutics, Inc. | 9 months$15M as of Sep 30, 2026Offering filed Oct 23, 2026, after this date | None on file | None | +36% | None scheduled | Oct 23, 2026Private placement | |
BOLT: 49 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| QCLSQ/C TECHNOLOGIES, INC. | 13 months$11M as of Sep 30, 2026 | None on file | Feb 11, 2026S-3 | +107% | None scheduled | Dec 9, 2025Private placement | |
QCLS: 48 points, Elevated
|
|||||||
| CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS, IN | 13 months$6.8M as of Sep 30, 2026 | None on file | Oct 4, 2024S-3 | +194% | None scheduled | Sep 25, 2026Private placement | |
CELZ: 48 points, Elevated
|
|||||||
| ALLRAllarity Therapeutics, Inc. | 14 months$17M as of Sep 30, 2026Offering filed Nov 17, 2026, after this date | Sep 9, 2024max $50Mfiled over 2 years ago | Dec 3, 2025S-3, $50M | +1% | None scheduled | Nov 17, 2026Private placement | |
ALLR: 48 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PROKPROKIDNEY CORP. | 15 months$210M as of Sep 30, 2026Offering filed Nov 12, 2026, after this date | Oct 29, 2026max $200M | Oct 29, 2026S-3, $200M | n/a | None scheduled | Nov 12, 2026Direct / best efforts | |
PROK: 48 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| TRDAEntrada Therapeutics, Inc. | 19 months$193M as of Sep 30, 2026 | Nov 6, 2025max $150M | Nov 6, 2025S-3, $150M | +2% | None scheduled | Jun 24, 2024Direct / best efforts | |
TRDA: 48 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CABACabaletta Bio, Inc. | 21 months$299M as of Sep 30, 2026 | Aug 7, 2025max $150M | Aug 7, 2025S-3, $150M | +124% | None scheduled | May 4, 2026Underwritten | |
CABA: 48 points, Elevated
|
|||||||
| RNTXRein Therapeutics, Inc. | 22 months$44M as of Sep 30, 2026 | Jul 30, 2025max $16M | May 16, 2025S-3, $150M | +228% | None scheduled | May 4, 2026Underwritten, $50M | |
RNTX: 48 points, Elevated
|
|||||||
| TTRXTurn Therapeutics Inc. | 23 months$9.4M as of Sep 30, 2026 | Nov 16, 2026max $50M | Nov 9, 2026S-3, $50M | +4% | None scheduled | Aug 18, 2026Private placement | |
TTRX: 48 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CATXPerspective Therapeutics, Inc. | 23 months$202M as of Sep 30, 2026 | Feb 3, 2026max $500M | May 24, 2024S-3ASR | +62% | None scheduled | Mar 6, 2024Private placement | |
CATX: 48 points, Elevated
|
|||||||
| EDSAEdesa Biotech, Inc. | 12 months$10M as of Jun 30, 2026Offering filed Aug 20, 2026, after this date | Dec 12, 2025max $2.3M | Jul 25, 2025S-3, $150M | +37% | None scheduled | Aug 20, 2026Underwritten | |
EDSA: 47 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MISTMilestone Pharmaceuticals Inc. | 18 months$145M as of Sep 30, 2026 | May 13, 2026max $100M | May 13, 2026S-3, $300M | +46% | None scheduled | Jul 14, 2025Underwritten | |
MIST: 47 points, Elevated
|
|||||||
| TNYATenaya Therapeutics, Inc. | 19 months$67M as of Sep 30, 2026 | Mar 21, 2025max $70M | Mar 21, 2025S-3, $300M | +37% | None scheduled | Dec 12, 2025Underwritten, $60M | |
TNYA: 47 points, Elevated
|
|||||||
| ACOGAlpha Cognition Inc. | 19 months$38M as of Jun 30, 2026 | Aug 22, 2025max $75M | Aug 22, 2025S-3, $75M | +35% | None scheduled | Oct 1, 2025Underwritten | |
ACOG: 47 points, Elevated
|
|||||||
| IRDOpus Genetics, Inc. | 21 months$89M as of Sep 30, 2026 | Aug 7, 2026max $125M | Aug 7, 2026S-3, $300M | +40% | None scheduled | Apr 7, 2026Private placement | |
IRD: 47 points, Elevated
|
|||||||
| UNCYUnicycive Therapeutics, Inc. | 27 months$61M as of Sep 30, 2026 | Jun 5, 2026max $50M | Jun 5, 2026S-3, $50M | +36% | Mar 25, 2027in 127 days | Mar 14, 2024Private placement | |
UNCY: 47 points, Elevated
|
|||||||
| ABVCABVC BIOPHARMA, INC. | 31 months$3.5M pro forma for events after Sep 30, 2026 | Aug 17, 2026size not stated | May 22, 2025S-3, $100M | +11% | None scheduled | Nov 2, 2026Private placement | |
ABVC: 47 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MLYSMineralys Therapeutics, Inc. | 50 months$625M as of Sep 30, 2026 | Jun 3, 2026size not stated | Nov 10, 2025S-3ASR, $300M | +12% | Dec 22, 2026in 34 days | Feb 8, 2024Private placement | |
MLYS: 47 points, Elevated
|
|||||||
| BKHABlack Hawk Acquisition Corp | 0 months$0.0M as of Aug 31, 2026Offering filed Sep 24, 2026, after this date | None on file | None | 0% | None scheduled | Sep 24, 2026Private placement | |
BKHA: 45 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| XRTXXORTX Therapeutics Inc. | 1 months$0.3M as of Dec 31, 2025Offering filed May 15, 2026, after this date | Dec 13, 2024max $1.0M | None | n/a | None scheduled | May 15, 2026Direct / best efforts | |
XRTX: 45 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| LITSLite Strategy, Inc. | 8 months$4.3M as of Sep 30, 2026Offering filed Nov 3, 2026, after this date | Jul 23, 2025max $100M | Feb 20, 2024S-3, $10M | -19% | None scheduled | Nov 3, 2026Private placement | |
LITS: 45 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ALVOAlvotech | 9 months$143M as of Dec 31, 2025 | Jun 16, 2026size not stated | None | +3% | None scheduled | None in 3 years | |
ALVO: 45 points, Elevated
|
|||||||
| CURXCuranex Pharmaceuticals Inc | 9 months$2.9M as of Sep 30, 2026 | None on file | None | -95%split likely, not scored | None scheduled | Sep 29, 2025Private placement | |
CURX: 45 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ONCOOnconetix, Inc. | 9 months$5.9M as of Sep 30, 2026 | None on file | None | -47% | None scheduled | Jul 29, 2026Private placement | |
ONCO: 45 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| GTBPGT Biopharma, Inc. | 10 months$9.9M as of Sep 30, 2026 | None on file | None | -80%split likely, not scored | None scheduled | Sep 21, 2026Private placement | |
GTBP: 45 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| SRRKScholar Rock Holding Corp | 16 months$414M as of Sep 30, 2026 | Aug 6, 2026max $200M | Oct 7, 2024S-3ASR | +20% | None scheduled | Oct 9, 2024Underwritten | |
SRRK: 45 points, Elevated
|
|||||||
| VYGRVoyager Therapeutics, Inc. | 17 months$132M as of Sep 30, 2026 | Nov 10, 2025max $100M | Nov 10, 2025S-3, $400M | +12% | None scheduled | Jan 8, 2024Underwritten | |
VYGR: 45 points, Elevated
|
|||||||
| IMNMImmunome Inc. | 23 months$462M as of Sep 30, 2026Offering filed Oct 5, 2026, after this date | Nov 9, 2026max $134M | Nov 9, 2026S-3ASR, $200M | +29% | Apr 28, 2027in 161 days | Oct 5, 2026Private placement | |
IMNM: 45 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| TARAProtara Therapeutics, Inc. | 25 months$143M as of Sep 30, 2026 | May 28, 2026max $100M | May 14, 2026S-3, $111M | +60% | None scheduled | Dec 5, 2025Underwritten, $75M | |
TARA: 45 points, Elevated
|
|||||||
| LPCNLipocine Inc. | 27 months$21M as of Sep 30, 2026 | Feb 26, 2026max $50M | Nov 22, 2023S-3, $150M | +100% | None scheduled | None in 3 years | |
LPCN: 45 points, Elevated
|
|||||||
| OVIDOvid Therapeutics Inc. | 29 months$161M as of Sep 30, 2026 | Nov 10, 2026max $75M | Nov 10, 2026S-3, $250M | +165% | None scheduled | Mar 18, 2026Private placement | |
OVID: 45 points, Elevated
|
|||||||
| ALLOAllogene Therapeutics, Inc. | 37 months$414M as of Sep 30, 2026 | Jun 22, 2026max $135M | Aug 12, 2026S-3 | +54% | None scheduled | None in 3 years | |
ALLO: 45 points, Elevated
|
|||||||
| CBIOCRESCENT BIOPHARMA, INC. | 37 months$289M as of Sep 30, 2026 | Jul 15, 2026size not stated | Jul 1, 2026S-3, $200M | +180% | None scheduled | Dec 4, 2025Private placement | |
CBIO: 45 points, Elevated
|
|||||||
| IKTInhibikase Therapeutics, Inc. | 39 months$193M as of Sep 30, 2026 | Dec 19, 2025max $185M | Jun 20, 2025S-3, $200M | +87% | None scheduled | Jul 29, 2026Private placement | |
IKT: 45 points, Elevated
|
|||||||
| ARTVArtiva Biotherapeutics, Inc. | 39 months$319M as of Sep 30, 2026 | Aug 6, 2026max $100M | Aug 6, 2026S-3, $100M | +101% | None scheduled | Jul 22, 2024Underwritten, $167M | |
ARTV: 45 points, Elevated
|
|||||||
| JBIOJade Biosciences, Inc. | 41 months$461M as of Sep 30, 2026 | Jun 4, 2026size not stated | May 7, 2026S-3, $200M | +50% | None scheduled | Dec 15, 2025Private placement | |
JBIO: 45 points, Elevated
|
|||||||
| ALTAltimmune, Inc. | 47 months$480M as of Sep 30, 2026 | Nov 6, 2025max $200M | Nov 6, 2025S-3, $200M | +87% | None scheduled | Apr 24, 2026Underwritten | |
ALT: 45 points, Elevated
|
|||||||
| SABSSAB Biotherapeutics, Inc. | 50 months$190M as of Sep 30, 2026 | Dec 29, 2025max $75M | Dec 29, 2025S-3, $300M | +89% | None scheduled | Mar 19, 2026Underwritten | |
SABS: 45 points, Elevated
|
|||||||
| NKTRNEKTAR THERAPEUTICS | 52 months$1.05B as of Sep 30, 2026 | May 8, 2026max $150M | Nov 12, 2025S-3ASR | +68% | None scheduled | Apr 23, 2026Underwritten, $325M | |
NKTR: 45 points, Elevated
|
|||||||
| QUITACHIEVE LIFE SCIENCES, INC. | 55 months$202M as of Sep 30, 2026 | Aug 14, 2026max $150M | Jan 23, 2026S-3, $300M | +107% | None scheduled | Apr 16, 2026Private placement | |
QUIT: 45 points, Elevated
|
|||||||
| ACHVACHIEVE LIFE SCIENCES, INC. | 64 months$204M as of Sep 30, 2026 | Aug 14, 2026max $150M | Jan 23, 2026S-3, $300M | +107% | None scheduled | Apr 16, 2026Private placement | |
ACHV: 45 points, Elevated
|
|||||||
| IMMXImmix Biopharma, Inc. | 84 months$336M as of Sep 30, 2026 | Jun 3, 2025max $13M | Jan 9, 2026S-3, $750M | +150% | None scheduled | Sep 29, 2026Underwritten, $125M | |
IMMX: 45 points, Elevated
|
|||||||
| SRZNSurrozen, Inc./DE | 108 months$220M pro forma for events after Sep 30, 2026 | Nov 16, 2026max $50M | Mar 23, 2026S-3, $50M | +122% | None scheduled | Oct 20, 2026Private placement | |
SRZN: 45 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| QTTBQ32 Bio Inc. | 232 months$290M as of Sep 30, 2026 | Jul 15, 2026size not stated | Jun 25, 2026S-3, $300M | +143% | None scheduled | Jul 13, 2026Underwritten | |
QTTB: 45 points, Elevated
|
|||||||
| PTHSPelthos Therapeutics Inc. | 7 months$24M as of Sep 30, 2026Offering filed Oct 30, 2026, after this date | None on file | Feb 2, 2026S-3, $200M | +28% | None scheduled | Oct 30, 2026Private placement | |
PTHS: 44 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| DMACDiaMedica Therapeutics Inc. | 12 months$35M as of Sep 30, 2026 | Aug 12, 2025max $100M | Aug 12, 2025S-3, $100M | +4% | None scheduled | Jul 21, 2025Private placement | |
DMAC: 43 points, Elevated
|
|||||||
| NSRXNasus Pharma Ltd | 14 months$12M as of Dec 31, 2025 | Sep 18, 2026max $8.5M | Sep 1, 2026F-3 | n/a | None scheduled | Aug 14, 2025Underwritten, $10M | |
NSRX: 43 points, Elevated
|
|||||||
| INKTMiNK Therapeutics, Inc. | 14 months$8.8M as of Sep 30, 2026 | Nov 7, 2025max $50M | Nov 7, 2025S-3, $150M | +9% | None scheduled | May 16, 2024Private placement | |
INKT: 43 points, Elevated
|
|||||||
| ISPCiSpecimen Inc. | 14 months$9.4M pro forma for events after Jun 30, 2026 | None on file | Oct 23, 2025S-3, $100M | -55%split likely, not scored | None scheduled | Nov 9, 2026Private placement | |
ISPC: 43 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| STROSUTRO BIOPHARMA, INC. | 14 months$142M as of Sep 30, 2026 | Mar 23, 2026max $100M | Mar 23, 2026S-3, $100M | -81%split likely, not scored | None scheduled | Feb 10, 2026Underwritten | |
STRO: 43 points, Elevated
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| IBRXImmunityBio, Inc. | 14 months$334M as of Sep 30, 2026 | Dec 29, 2025max $460M | Apr 17, 2024S-3ASR, $301M | +8% | None scheduled | Jul 28, 2025Direct / best efforts | |
IBRX: 43 points, Elevated
|
|||||||
| VNDAVanda Pharmaceuticals Inc. | 14 months$140M as of Sep 30, 2026 | None on file | Feb 12, 2026S-3 | +2% | Dec 12, 2026in 24 days | None in 3 years | |
VNDA: 43 points, Elevated
|
|||||||
| FATEFATE THERAPEUTICS INC | 15 months$139M as of Sep 30, 2026 | Nov 12, 2026max $100M | Nov 5, 2026S-3, $100M | +5% | None scheduled | Mar 21, 2024Private placement | |
FATE: 43 points, Elevated
|
|||||||
| MREOMereo BioPharma Group plc | 16 months$26M as of Sep 30, 2026 | May 15, 2024max $50Mfiled over 2 years ago | May 15, 2024S-3, $50M | +0% | None scheduled | Jun 14, 2024Underwritten | |
MREO: 43 points, Elevated
|
|||||||
| ATYRaTYR PHARMA INC | 16 months$49M as of Sep 30, 2026 | Nov 6, 2026max $215M | Aug 7, 2025S-3, $300M | -97%split likely, not scored | None scheduled | None in 3 years | |
ATYR: 43 points, Elevated
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ALMSALUMIS INC. | 16 months$431M as of Sep 30, 2026 | None on file | Jul 3, 2025S-3, $400M | n/a | None scheduled | Jan 8, 2026Underwritten | |
ALMS: 43 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| AAPGASCENTAGE PHARMA GROUP INTERNATIONAL | 17 months$1.90B as of Dec 31, 2025 | Jul 20, 2026max $200M | Jul 20, 2026F-3ASR, $200M | +7% | None scheduled | Jan 24, 2025Underwritten | |
AAPG: 43 points, Elevated
|
|||||||
| RANIRani Therapeutics Holdings, Inc. | 17 months$48M as of Sep 30, 2026 | May 19, 2025max $17M | Aug 8, 2025S-3, $200M | n/a | None scheduled | May 27, 2026Direct / best efforts | |
RANI: 43 points, Elevated
|
|||||||
| NTLAIntellia Therapeutics, Inc. | 22 months$615M as of Sep 30, 2026 | Apr 29, 2026size not stated | Nov 24, 2023S-3ASR, $139M | +21% | Mar 10, 2027in 112 days | Mar 2, 2026Direct / best efforts | |
NTLA: 43 points, Elevated
|
|||||||
| EDITEditas Medicine, Inc. | 23 months$190M as of Sep 30, 2026 | Aug 31, 2026max $400M | Aug 31, 2026S-3, $400M | +58% | None scheduled | May 26, 2026Underwritten | |
EDIT: 43 points, Elevated
|
|||||||
| ALECAlector, Inc. | 14 months$139M as of Sep 30, 2026 | Oct 16, 2026max $125M | Mar 12, 2026S-3 | +36% | None scheduled | Jan 19, 2024Underwritten | |
ALEC: 42 points, Elevated
|
|||||||
| SLDBSolid Biosciences Inc. | 21 months$349M as of Sep 30, 2026 | Aug 6, 2026max $200M | Aug 6, 2026S-3ASR | +43% | None scheduled | Mar 6, 2026Private placement | |
SLDB: 42 points, Elevated
|
|||||||
| KLRSKalaris Therapeutics, Inc. | 23 months$83M as of Sep 30, 2026 | Apr 3, 2026max $100M | Apr 3, 2026S-3, $100M | +27% | None scheduled | Dec 18, 2025Private placement | |
KLRS: 42 points, Elevated
|
|||||||
| PRAXPraxis Precision Medicines, Inc. | 63 months$1.67B as of Sep 30, 2026 | Oct 20, 2025size not stated | Dec 23, 2024S-3ASR, $250M | +12% | Dec 27, 2026in 39 days | Jan 7, 2026Underwritten | |
PRAX: 42 points, Elevated
|
|||||||
| SLBTSL Science Holding Ltd | 14 months$3.4M as of Jun 12, 2026 | None on file | None | n/a | None scheduled | None in 3 years | |
SLBT: 41 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| CGEMCullinan Therapeutics, Inc. | 23 months$311M as of Sep 30, 2026 | Apr 28, 2026max $200M | Apr 28, 2026S-3ASR, $200M | +10% | Feb 27, 2027in 101 days | Apr 16, 2024Private placement | |
CGEM: 41 points, Elevated
|
|||||||
| NIVFNewGenIvf Group Ltd | 4 months$4.4M as of Dec 31, 2025Offering filed Aug 20, 2026, after this date | None on file | Oct 27, 2026F-3 | n/a | None scheduled | Aug 20, 2026Direct / best efforts | |
NIVF: 40 points, Elevated
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| OGIORGANIGRAM GLOBAL INC. | 5 months$12M as of Sep 30, 2025 | None on file | None | n/a | None scheduled | None in 3 years | |
OGI: 40 points, Elevated
|
|||||||
| KPRXKIORA PHARMACEUTICALS INC | 20 months$17M as of Sep 30, 2026 | None on file | Sep 15, 2025S-3, $100M | +20% | None scheduled | Apr 7, 2026Private placement | |
KPRX: 40 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| IMVTImmunovant, Inc. | 21 months$722M as of Sep 30, 2026 | Nov 9, 2026max $150M | Nov 9, 2026S-3ASR, $150M | +18% | None scheduled | Jan 13, 2025Private placement | |
IMVT: 40 points, Elevated
|
|||||||
| VKTXViking Therapeutics, Inc. | 22 months$960M as of Sep 30, 2026 | Jul 30, 2026max $500M | Jul 30, 2026S-3ASR, $500M | +13% | None scheduled | Sep 25, 2026Convertible, $275M | |
VKTX: 40 points, Elevated
|
|||||||
| IMTXImmatics N.V. | 23 months$393M as of Dec 31, 2025 | Dec 5, 2025size not stated | Mar 27, 2025F-3, $500M | +10% | None scheduled | Jan 19, 2024Underwritten, $175M | |
IMTX: 40 points, Elevated
|
|||||||
| ABSIAbsci Corp | 23 months$218M as of Jun 30, 2026 | Jun 24, 2026size not stated | Nov 12, 2026S-3ASR | +15% | None scheduled | Jul 25, 2025Underwritten, $50M | |
ABSI: 40 points, Elevated
|
|||||||
| APREAprea Therapeutics, Inc. | 32 months$38M as of Sep 30, 2026 | Nov 8, 2024max $3.0Mfiled over 2 years ago | Jan 26, 2024S-3, $150M | +125% | None scheduled | Mar 30, 2026Private placement | |
APRE: 40 points, Elevated
|
|||||||
| ANABANAPTYSBIO, INC | 36 months$213M as of Jun 30, 2026 | Nov 15, 2024max $100Mfiled over 2 years ago | Nov 5, 2024S-3, $150M | +8% | Dec 12, 2026in 24 days | Aug 14, 2024Underwritten | |
ANAB: 40 points, Elevated
|
|||||||
| INDPIndaptus Therapeutics, Inc. | 55 months$31M as of Sep 30, 2026 | Aug 6, 2024size not statedfiled over 2 years ago | Aug 13, 2025S-3, $200M | +8,672%split likely, not scored | None scheduled | Sep 10, 2026Private placement | |
INDP: 40 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| INSMINSMED Inc | 55 months$1.15B as of Sep 30, 2026 | Feb 22, 2024max $500Mfiled over 2 years ago | May 15, 2026S-3ASR | +3% | Jan 28, 2027in 71 days | Jun 12, 2025Underwritten, $750M | |
INSM: 40 points, Elevated
|
|||||||
| TILInstil Bio, Inc. | 70 months$70M as of Sep 30, 2026 | Mar 31, 2025max $100M | Nov 13, 2024S-3, $200M | 0% | None scheduled | None in 3 years | |
TIL: 40 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BBIOBridgeBio Pharma, Inc. | 80 months$1.54B as of Sep 30, 2026 | May 8, 2026max $500M | May 8, 2026S-3ASR, $500M | +1% | Nov 27, 2026in 9 days | Jul 2, 2026Private placement | |
BBIO: 40 points, Elevated
|
|||||||
| SXTCChina SXT Pharmaceuticals, Inc. | 85 months$28M as of Mar 31, 2026 | Jun 1, 2026max $100M | Jul 7, 2026F-3 | n/a | None scheduled | Jan 12, 2026Direct / best efforts | |
SXTC: 40 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| HOWLWerewolf Therapeutics, Inc. | 108 months$42M as of Sep 30, 2026 | May 8, 2025max $12M | May 8, 2025S-3, $150M | +0% | None scheduled | Aug 21, 2026Private placement | |
HOWL: 40 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| ARTLARTELO BIOSCIENCES, INC. | n/a$0.0M as of Sep 30, 2026 | May 26, 2026max $6.5M | May 4, 2026S-3, $69M | -54%split likely, not scored | None scheduled | Mar 30, 2026Private placement | |
ARTL: 40 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| HYFTMindWalk Holdings Corp. | n/a | Jul 13, 2026max $30M | Jul 13, 2026F-3, $250M | +1% | None scheduled | Dec 7, 2023Underwritten | |
HYFT: 40 points, Elevated
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PRLDPrelude Therapeutics Inc | 25 months$140M as of Sep 30, 2026 | Mar 12, 2026max $25M | May 30, 2024S-3, $400M | +27% | None scheduled | Nov 4, 2025Private placement | |
PRLD: 39 points, Moderate
|
|||||||
| NVCTNuvectis Pharma, Inc. | 28 months$141M as of Sep 30, 2026 | Aug 21, 2026max $75M | Aug 21, 2026S-3, $200M | +34% | None scheduled | Feb 6, 2025Underwritten, $14M | |
NVCT: 39 points, Moderate
|
|||||||
| AVBPArriVent BioPharma, Inc. | 29 months$393M as of Sep 30, 2026 | May 11, 2026max $250M | Feb 3, 2025S-3ASR, $250M | +25% | None scheduled | Jul 2, 2025Underwritten, $86M | |
AVBP: 39 points, Moderate
|
|||||||
| WHWKWhitehawk Therapeutics, Inc. | 30 months$170M as of Sep 30, 2026 | Apr 25, 2025max $75M | Feb 12, 2024S-3, $150M | +25% | None scheduled | May 13, 2026Private placement | |
WHWK: 39 points, Moderate
|
|||||||
| ENGNenGene Therapeutics Inc. | 32 months$266M as of Jul 31, 2026 | Mar 9, 2026max $100M | Feb 19, 2026S-3 | +31% | None scheduled | Jan 21, 2026Private placement | |
ENGN: 39 points, Moderate
|
|||||||
| ANTXAN2 Therapeutics, Inc. | 37 months$80M as of Sep 30, 2026 | Apr 20, 2026max $80M | Apr 9, 2026S-3, $300M | +39% | None scheduled | Mar 10, 2026Private placement | |
ANTX: 39 points, Moderate
|
|||||||
| XENEXenon Pharmaceuticals Inc. | 37 months$1.15B as of Sep 30, 2026 | Mar 12, 2026size not stated | Aug 9, 2024S-3ASR | +27% | None scheduled | Nov 29, 2023Underwritten | |
XENE: 39 points, Moderate
|
|||||||
| GLUEMonte Rosa Therapeutics, Inc. | 41 months$578M as of Sep 30, 2026 | Feb 11, 2026max $100M | Feb 11, 2026S-3ASR, $100M | +31% | None scheduled | May 16, 2024Underwritten | |
GLUE: 39 points, Moderate
|
|||||||
| OKYOOKYO Pharma Ltd | 42 months$21M as of Mar 31, 2026 | Feb 11, 2026max $50M | Feb 2, 2026F-3, $200M | +40% | None scheduled | Feb 17, 2026Underwritten, $20M | |
OKYO: 39 points, Moderate
|
|||||||
| ANROAlto Neuroscience, Inc. | 47 months$319M as of Sep 30, 2026 | Feb 3, 2025max $75M | Feb 3, 2025S-3, $75M | +29% | None scheduled | Jul 14, 2026Underwritten | |
ANRO: 39 points, Moderate
|
|||||||
| NBPNovaBridge Biosciences | 50 months$191M as of Dec 31, 2025 | Jul 11, 2025max $50M | May 2, 2025F-3, $250M | +42% | None scheduled | Aug 4, 2025Underwritten | |
NBP: 39 points, Moderate
|
|||||||
| RLMDRELMADA THERAPEUTICS, INC. | 55 months$202M as of Sep 30, 2026 | Jan 30, 2026max $100M | May 13, 2026S-3ASR | +46% | None scheduled | Mar 9, 2026Private placement | |
RLMD: 39 points, Moderate
|
|||||||
| SLSSELLAS Life Sciences Group, Inc. | 60 months$135M as of Sep 30, 2026 | Mar 20, 2026max $150M | Mar 20, 2026S-3ASR, $150M | +43% | None scheduled | Sep 11, 2025Private placement | |
SLS: 39 points, Moderate
|
|||||||
| FULCFulcrum Therapeutics, Inc. | 63 months$307M as of Sep 30, 2026 | Feb 27, 2024max $100Mfiled over 2 years ago | Feb 27, 2024S-3 | +41% | None scheduled | Aug 17, 2026Private placement | |
FULC: 39 points, Moderate
|
|||||||
| TNGXTango Therapeutics, Inc. | 77 months$978M as of Sep 30, 2026 | Aug 11, 2026max $100M | Nov 21, 2025S-3ASR, $100M | +26% | None scheduled | Jun 10, 2026Underwritten | |
TNGX: 39 points, Moderate
|
|||||||
| MIRMMirum Pharmaceuticals, Inc. | 83 months$670M as of Sep 30, 2026 | Aug 12, 2025max $200M | Aug 12, 2025S-3ASR, $200M | +27% | None scheduled | May 18, 2026Private placement | |
MIRM: 39 points, Moderate
|
|||||||
| ORKAOruka Therapeutics, Inc. | 93 months$1.21B as of Sep 30, 2026 | Aug 28, 2026max $500M | Aug 21, 2026S-3, $500M | +40% | None scheduled | Apr 29, 2026Underwritten, $700M | |
ORKA: 39 points, Moderate
|
|||||||
| HKPDCellyan Biotechnology Co., Ltd | n/a | None on file | Jun 12, 2026F-3, $200M | +49% | None scheduled | None in 3 years | |
HKPD: 39 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BSEMBioStem Technologies, Inc. | 1 months$1.0M as of Jun 30, 2026Offering filed Sep 30, 2026, after this date | None on file | None | n/a | None scheduled | Sep 30, 2026Private placement | |
BSEM: 38 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ANNXAnnexon, Inc. | 13 months$213M as of Sep 30, 2026 | Mar 31, 2026max $150M | Mar 31, 2026S-3ASR, $150M | +1% | None scheduled | Nov 13, 2025Underwritten | |
ANNX: 38 points, Moderate
|
|||||||
| UPBUpstream Bio, Inc. | 14 months$207M as of Sep 30, 2026 | Mar 26, 2026max $150M | Nov 5, 2025S-3ASR | +1% | None scheduled | Oct 11, 2024Underwritten, $255M | |
UPB: 38 points, Moderate
|
|||||||
| PMNProMIS Neurosciences Inc. | 14 months$53M as of Sep 30, 2026 | Mar 25, 2026max $50M | Mar 25, 2026S-3, $50M | -83%split likely, not scored | None scheduled | Jan 30, 2026Private placement | |
PMN: 38 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| MAIAMAIA Biotechnology, Inc. | 15 months$28M as of Sep 30, 2026 | None on file | Aug 21, 2026S-3 | +67% | None scheduled | Mar 4, 2026Underwritten, $30M | |
MAIA: 38 points, Moderate
|
|||||||
| DTILPRECISION BIOSCIENCES INC | 17 months$82M as of Sep 30, 2026Offering filed Nov 6, 2026, after this date | Dec 30, 2025max $60M | Dec 30, 2025S-3, $60M | +111% | None scheduled | Nov 6, 2026Underwritten | |
DTIL: 38 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| AVIRAtea Pharmaceuticals, Inc. | 17 months$191M as of Sep 30, 2026 | Nov 7, 2024max $200Mfiled over 2 years ago | Nov 7, 2024S-3, $200M | +3% | None scheduled | None in 3 years | |
AVIR: 38 points, Moderate
|
|||||||
| COGTCogent Biosciences, Inc. | 30 months$791M as of Sep 30, 2026 | Aug 10, 2026max $400M | Nov 7, 2025S-3ASR, $300M | +22% | Nov 30, 2026in 12 days | Nov 12, 2025Convertible | |
COGT: 37 points, Moderate
|
|||||||
| IBIOiBio, Inc. | 30 months$77M as of Sep 30, 2026 | Mar 6, 2026max $100M | Feb 27, 2026S-3, $200M | +213% | None scheduled | Jan 12, 2026Private placement | |
IBIO: 35 points, Moderate
|
|||||||
| KZIAKAZIA THERAPEUTICS LTD | 58 months$69M as of Jun 30, 2025Offering filed Aug 31, 2026, after this date | Aug 28, 2026max $80M | Mar 18, 2026F-3, $100M | +143% | None scheduled | Aug 31, 2026Underwritten | |
KZIA: 35 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CMPSCOMPASS Pathways plc | 29 months$444M as of Sep 30, 2026 | May 8, 2025max $150M | Aug 5, 2026S-3ASR | +48% | None scheduled | Feb 19, 2026Underwritten | |
CMPS: 34 points, Moderate
|
|||||||
| CADLCandel Therapeutics, Inc. | 30 months$203M as of Sep 30, 2026 | Nov 12, 2026max $50M | Aug 14, 2025S-3, $50M | +43% | None scheduled | Feb 20, 2026Underwritten, $100M | |
CADL: 34 points, Moderate
|
|||||||
| RXRXRECURSION PHARMACEUTICALS, INC. | 18 months$550M as of Sep 30, 2026Offering filed Oct 15, 2026, after this date | Feb 25, 2026max $300M | Feb 12, 2025S-3ASR | n/a | None scheduled | Oct 15, 2026Underwritten | |
RXRX: 33 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| OCGNOcugen, Inc. | 18 months$84M as of Sep 30, 2026 | None on file | Apr 18, 2024S-3, $175M | +9% | None scheduled | May 14, 2026Private placement | |
OCGN: 33 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| IMUXIMMUNIC, INC. | 19 months$155M as of Sep 30, 2026 | Jun 10, 2024max $80Mfiled over 2 years ago | Nov 22, 2023S-3, $250M | -87%split likely, not scored | None scheduled | Feb 13, 2026Private placement | |
IMUX: 33 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ARWRARROWHEAD PHARMACEUTICALS, INC. | 19 months$1.19B as of Sep 30, 2026 | Dec 11, 2025max $500M | Dec 11, 2025S-3ASR, $500M | +4% | None scheduled | Jan 9, 2026Convertible | |
ARWR: 33 points, Moderate
|
|||||||
| LENZLENZ Therapeutics, Inc. | 19 months$197M as of Sep 30, 2026 | Apr 14, 2025max $150M | Apr 4, 2025S-3, $500M | +0% | None scheduled | Jul 15, 2024Private placement | |
LENZ: 33 points, Moderate
|
|||||||
| ALZNAlzamend Neuro, Inc. | 20 months$7.6M as of Jul 31, 2026Offering filed Aug 3, 2026, after this date | Mar 6, 2026max $3.0M | None | +54% | None scheduled | Aug 3, 2026Private placement | |
ALZN: 33 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ANIXAnixa Biosciences Inc | 20 months$14M as of Jul 31, 2026 | Sep 10, 2025max $200M | Sep 10, 2025S-3, $200M | +6% | None scheduled | None in 3 years | |
ANIX: 33 points, Moderate
|
|||||||
| PLXProtalix BioTherapeutics, Inc. | 20 months$22M as of Sep 30, 2026 | Aug 22, 2025max $20M | Apr 28, 2025S-3 | +5% | None scheduled | None in 3 years | |
PLX: 33 points, Moderate
|
|||||||
| MGXMetagenomi Therapeutics, Inc. | 21 months$138M as of Sep 30, 2026 | Mar 17, 2025max $75M | Mar 17, 2025S-3, $75M | n/a | None scheduled | Feb 12, 2024Underwritten, $94M | |
MGX: 33 points, Moderate
|
|||||||
| VTVTvTv Therapeutics Inc. | 21 months$77M as of Sep 30, 2026 | Apr 10, 2024max $13Mfiled over 2 years ago | Apr 10, 2024S-3, $250M | n/a | None scheduled | None in 3 years | |
VTVT: 33 points, Moderate
|
|||||||
| NERVMinerva Neurosciences, Inc. | 22 months$77M as of Sep 30, 2026 | May 27, 2026max $75M | Mar 11, 2026S-3, $200M | +613%split likely, not scored | None scheduled | Oct 22, 2025Private placement | |
NERV: 33 points, Moderate
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| QNRXQuoin Pharmaceuticals Ltd. | 22 months$33M as of Sep 30, 2026 | Nov 4, 2026max $11M | Oct 28, 2026S-3, $150M | n/a | None scheduled | Aug 28, 2026Private placement | |
QNRX: 33 points, Moderate
|
|||||||
| EVAXEvaxion A/S | 24 months$14M as of Dec 31, 2025 | Dec 10, 2025max $46M | Mar 13, 2025F-3, $100M | +495%split likely, not scored | None scheduled | Jan 31, 2025Direct / best efforts | |
EVAX: 33 points, Moderate
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| DNAGinkgo Bioworks Holdings, Inc. | 24 months$285M as of Sep 30, 2026 | Sep 4, 2025max $100M | Aug 7, 2025S-3 | n/a | None scheduled | None in 3 years | |
DNA: 33 points, Moderate
|
|||||||
| AQSTAquestive Therapeutics, Inc. | 33 months$90M as of Sep 30, 2026 | Apr 3, 2024max $100Mfiled over 2 years ago | Apr 3, 2024S-3, $250M | +3% | Mar 16, 2027in 118 days | May 13, 2026Private placement | |
AQST: 33 points, Moderate
|
|||||||
| AXSMAxsome Therapeutics, Inc. | 44 months$314M as of Sep 30, 2026 | Nov 3, 2025max $250M | Nov 3, 2025S-3ASR, $250M | +4% | May 1, 2027in 164 days | May 13, 2025Private placement | |
AXSM: 33 points, Moderate
|
|||||||
| HINDVyome Holdings, Inc | 27 months$7.0M as of Sep 30, 2026 | Aug 20, 2025size not stated | May 9, 2025S-3 | +24% | None scheduled | Aug 19, 2025Private placement | |
HIND: 32 points, Moderate
|
|||||||
| VRDNViridian Therapeutics, Inc.\DE | 29 months$955M as of Sep 30, 2026 | Sep 5, 2025max $300M | Sep 5, 2025S-3ASR, $300M | +19% | None scheduled | May 8, 2026Convertible, $125M | |
VRDN: 32 points, Moderate
|
|||||||
| RVMDRevolution Medicines, Inc. | 31 months$4.19B as of Sep 30, 2026 | Feb 25, 2026max $1.00B | May 8, 2024S-3ASR | +12% | None scheduled | Apr 15, 2026Convertible | |
RVMD: 32 points, Moderate
|
|||||||
| CYTKCYTOKINETICS INC | 34 months$1.58B as of Sep 30, 2026 | May 7, 2026max $500M | Feb 27, 2025S-3ASR, $500M | +14% | None scheduled | Sep 22, 2025Private placement | |
CYTK: 32 points, Moderate
|
|||||||
| IOVAIOVANCE BIOTHERAPEUTICS, INC. | 37 months$398M as of Sep 30, 2026 | Aug 22, 2025max $350M | Jun 18, 2026S-3ASR, $90M | +17% | None scheduled | Feb 21, 2024Underwritten | |
IOVA: 32 points, Moderate
|
|||||||
| IDYAIDEAYA Biosciences, Inc. | 38 months$1.15B as of Sep 30, 2026 | Jun 9, 2026size not stated | May 5, 2026S-3ASR | +10% | None scheduled | Jul 10, 2024Underwritten | |
IDYA: 32 points, Moderate
|
|||||||
| DSGNDesign Therapeutics, Inc. | 41 months$209M as of Sep 30, 2026 | Nov 4, 2026max $100M | Nov 4, 2026S-3, $300M | +12% | None scheduled | None in 3 years | |
DSGN: 32 points, Moderate
|
|||||||
| IMAImageneBio, Inc. | 41 months$127M as of Sep 30, 2026 | Aug 5, 2026max $17M | Aug 5, 2026S-3, $200M | +11% | None scheduled | Apr 13, 2026Private placement | |
IMA: 32 points, Moderate
|
|||||||
| TWSTTwist Bioscience Corp | 61 months$167M as of Sep 30, 2026 | Aug 5, 2026size not stated | Jun 18, 2026S-3ASR | +12% | None scheduled | Feb 17, 2026Private placement | |
TWST: 32 points, Moderate
|
|||||||
| CGONCG Oncology, Inc. | 63 months$984M as of Sep 30, 2026 | Aug 6, 2026max $550M | Mar 28, 2025S-3ASR, $250M | +11% | None scheduled | Jan 25, 2024Underwritten, $380M | |
CGON: 32 points, Moderate
|
|||||||
| LXRXLEXICON PHARMACEUTICALS, INC. | 64 months$183M as of Sep 30, 2026 | Nov 6, 2025max $75M | Aug 2, 2024S-3 | +23% | None scheduled | May 6, 2026Private placement | |
LXRX: 32 points, Moderate
|
|||||||
| CTNMContineum Therapeutics, Inc. | 65 months$244M as of Sep 30, 2026 | Mar 5, 2026max $100M | May 14, 2025S-3, $75M | +22% | None scheduled | Apr 8, 2024Underwritten, $110M | |
CTNM: 32 points, Moderate
|
|||||||
| ERASErasca, Inc. | 95 months$948M as of Sep 30, 2026 | Jul 14, 2026size not stated | Jul 13, 2026S-3ASR | +24% | None scheduled | May 17, 2024Underwritten | |
ERAS: 32 points, Moderate
|
|||||||
| BLTEBELITE BIO, INC | 160 months$492M as of Dec 31, 2025 | None on file | Jan 27, 2025F-3ASR | +24% | Feb 12, 2027in 86 days | Dec 2, 2025Underwritten | |
BLTE: 32 points, Moderate
|
|||||||
| PHATPhathom Pharmaceuticals, Inc. | 12169 months$185M as of Sep 30, 2026 | Jan 8, 2026size not stated | Jan 7, 2026S-3ASR | +14% | None scheduled | None in 3 years | |
PHAT: 32 points, Moderate
|
|||||||
| INBXInhibrx Biosciences, Inc. | 19 months$199M as of Jun 30, 2026Offering filed Jul 16, 2026, after this date | Nov 13, 2026max $150M | Nov 13, 2026S-3ASR, $150M | +2% | Apr 14, 2027in 147 days | Jul 16, 2026Private placement | |
INBX: 31 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PLYXPolaryx Therapeutics, Inc. | 20 months$12M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | May 28, 2026Private placement | |
PLYX: 31 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SPRCSciSparc Ltd. | 9 months$4.4M as of Dec 31, 2025Offering filed Jan 14, 2026, after this date | None on file | Nov 9, 2026F-3 | -97%split likely, not scored | None scheduled | Jan 14, 2026Direct / best efforts | |
SPRC: 30 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PBMPSYENCE BIOMEDICAL LTD. | 11 months$7.4M as of Mar 31, 2026 | None on file | None | +304%split likely, not scored | None scheduled | None in 3 years | |
PBM: 30 points, Moderate
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| QDELQuidelOrtho Corp | 11 months$166M as of Sep 27, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
QDEL: 30 points, Moderate
|
|||||||
| LCTXLineage Cell Therapeutics, Inc. | 23 months$50M as of Jun 30, 2026Offering filed Nov 12, 2026, after this date | Mar 11, 2026size not stated | Mar 11, 2026S-3, $100M | +11% | None scheduled | Nov 12, 2026Private placement | |
LCTX: 30 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| LYELLyell Immunopharma, Inc. | 24 months$270M as of Sep 30, 2026Offering filed Nov 4, 2026, after this date | May 6, 2024max $150Mfiled over 2 years ago | Feb 29, 2024S-3, $150M | +16% | None scheduled | Nov 4, 2026Private placement | |
LYEL: 30 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PHVSPharvaris N.V. | 25 months$318M as of Dec 31, 2025Offering filed May 8, 2026, after this date | Apr 12, 2024max $175Mfiled over 2 years ago | Apr 12, 2024F-3ASR | +20% | Apr 23, 2027in 156 days | May 8, 2026Underwritten | |
PHVS: 30 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| IPSCCentury Therapeutics, Inc. | 26 months$197M as of Sep 30, 2026 | Mar 26, 2026max $150M | Jul 10, 2025S-3, $200M | +108% | None scheduled | Jan 8, 2026Private placement | |
IPSC: 30 points, Moderate
|
|||||||
| AURAAura Biosciences, Inc. | 30 months$297M as of Sep 30, 2026 | Aug 11, 2026max $200M | Aug 11, 2026S-3, $500M | +64% | None scheduled | May 5, 2026Underwritten | |
AURA: 30 points, Moderate
|
|||||||
| JAGXJaguar Health, Inc. | 35 months$5.5M as of Sep 30, 2026Offering filed Nov 9, 2026, after this date | Sep 24, 2026size not stated | Oct 22, 2026S-3 | +1,087%split likely, not scored | None scheduled | Nov 9, 2026Underwritten | |
JAGX: 30 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| STTKShattuck Labs, Inc. | 43 months$197M as of Sep 30, 2026 | Jan 22, 2026max $75M | Jan 13, 2026S-3, $200M | +61% | None scheduled | Jun 11, 2026Underwritten, $55M | |
STTK: 30 points, Moderate
|
|||||||
| ASMBASSEMBLY BIOSCIENCES, INC. | 58 months$314M as of Jun 30, 2026 | Mar 19, 2026max $100M | Mar 19, 2026S-3, $400M | +165% | None scheduled | May 26, 2026Underwritten | |
ASMB: 30 points, Moderate
|
|||||||
| AVTXAvalo Therapeutics, Inc. | 75 months$393M as of Sep 30, 2026 | Nov 5, 2026max $200M | Jan 8, 2026S-3, $750M | +219% | None scheduled | Jun 12, 2026Private placement | |
AVTX: 30 points, Moderate
|
|||||||
| ENTXEntera Bio Ltd. | 147 months$266M as of Sep 30, 2026 | Jan 10, 2025size not stated | May 30, 2025S-3 | +280% | None scheduled | Jul 28, 2026Private placement | |
ENTX: 30 points, Moderate
|
|||||||
| KRROKorro Bio, Inc. | 25 months$125M as of Sep 30, 2026 | Dec 6, 2024max $100M | Dec 2, 2024S-3 | +46% | None scheduled | Aug 6, 2026Private placement | |
KRRO: 29 points, Moderate
|
|||||||
| ZLABZai Lab Ltd | 28 months$560M as of Sep 30, 2026Offering filed Oct 23, 2026, after this date | None on file | Apr 19, 2024S-3ASR | +30% | Nov 30, 2026in 12 days | Oct 23, 2026Private placement | |
ZLAB: 29 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ACRSAclaris Therapeutics, Inc. | 28 months$205M as of Sep 30, 2026Offering filed Oct 27, 2026, after this date | Aug 6, 2026max $150M | Aug 6, 2026S-3ASR, $150M | +46% | None scheduled | Oct 27, 2026Underwritten | |
ACRS: 29 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| BGMSBio Green Med Solution, Inc. | 32 months$3.5M as of Sep 30, 2026 | None on file | None | +35% | None scheduled | Jun 10, 2026Private placement | |
BGMS: 29 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| SAENGenenta Science S.p.A. | 49 months$28M as of Dec 31, 2025 | Jan 27, 2026max $30M | None | +28% | None scheduled | Oct 28, 2025Direct / best efforts, $15M | |
SAEN: 29 points, Moderate
|
|||||||
| SGMTSagimet Biosciences Inc. | 71 months$276M as of Sep 30, 2026Offering filed Oct 1, 2026, after this date | Aug 14, 2025max $75M | Aug 15, 2024S-3, $75M | +44% | None scheduled | Oct 1, 2026Underwritten | |
SGMT: 29 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CTMXCytomX Therapeutics, Inc. | 1470 months$348M as of Sep 30, 2026 | Aug 9, 2024max $750Mfiled over 2 years ago | Mar 16, 2026S-3ASR | +29% | None scheduled | Mar 18, 2026Underwritten | |
CTMX: 29 points, Moderate
|
|||||||
| GNTAGenenta Science S.p.A. | n/a | Jan 27, 2026max $30M | None | +28% | None scheduled | Oct 28, 2025Direct / best efforts, $15M | |
GNTA: 29 points, Moderate
|
|||||||
| SCYXSCYNEXIS INC | 13 months$47M as of Sep 30, 2026 | Nov 6, 2024max $50Mfiled over 2 years ago | Nov 5, 2026S-3, $200M | -76%split likely, not scored | None scheduled | Mar 31, 2026Private placement | |
SCYX: 28 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| SPROSpero Therapeutics, Inc. | 14 months$108M as of Sep 30, 2026 | Aug 28, 2026max $100M | Aug 28, 2026S-3, $100M | +3% | None scheduled | None in 3 years | |
SPRO: 28 points, Moderate
|
|||||||
| MOLNMOLECULAR PARTNERS AG | 15 months$57M as of Dec 31, 2025 | None on file | Apr 11, 2025F-3, $300M | 0% | None scheduled | Oct 25, 2024Underwritten | |
MOLN: 28 points, Moderate
|
|||||||
| IVAInventiva S.A. | 21 months$166M as of Dec 31, 2025Offering filed Jun 2, 2026, after this date | None on file | Jun 2, 2026F-3ASR | +102% | None scheduled | Jun 2, 2026Underwritten | |
IVA: 28 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| XLOXilio Therapeutics, Inc. | 23 months$122M as of Sep 30, 2026 | May 12, 2026max $250M | May 12, 2026S-3, $250M | -87%split likely, not scored | None scheduled | Feb 12, 2026Underwritten | |
XLO: 28 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| LXEOLexeo Therapeutics, Inc. | 29 months$219M as of Sep 30, 2026 | Mar 24, 2025max $75M | Oct 29, 2026S-3, $300M | +13% | None scheduled | Sep 29, 2026Private placement | |
LXEO: 27 points, Moderate
|
|||||||
| CRVSCorvus Pharmaceuticals, Inc. | 44 months$203M as of Sep 30, 2026 | Mar 13, 2026max $100M | Mar 13, 2026S-3ASR | +13% | None scheduled | Jan 23, 2026Underwritten | |
CRVS: 27 points, Moderate
|
|||||||
| RTSNRetension Pharmaceuticals, Inc. | 14 months$13M | None on file | None | n/a | None scheduled | Oct 9, 2026Underwritten, $45M | |
RTSN: 26 points, Moderate
|
|||||||
| ASPEAspen Neuroscience, Inc. | 15 months$72M | None on file | None | n/a | None scheduled | Oct 30, 2026Underwritten, $141M | |
ASPE: 26 points, Moderate
|
|||||||
| CRDLCardiol Therapeutics Inc. | 13 months$26M as of Dec 31, 2025 | None on file | None | +21% | None scheduled | None in 3 years | |
CRDL: 25 points, Moderate
|
|||||||
| WVEWave Life Sciences, Inc. | 23 months$431M as of Sep 30, 2026 | None on file | Nov 12, 2024S-3ASR, $250M | +18% | None scheduled | Dec 11, 2025Underwritten | |
WVE: 25 points, Moderate
|
|||||||
| NKTXNkarta, Inc. | 26 months$213M as of Sep 30, 2026 | Apr 3, 2026max $100M | Mar 25, 2026S-3, $350M | +1% | None scheduled | Mar 26, 2024Underwritten | |
NKTX: 25 points, Moderate
|
|||||||
| FHTXFoghorn Therapeutics Inc. | 26 months$156M as of Sep 30, 2026 | Mar 20, 2025max $100M | Jan 24, 2025S-3 | +6% | None scheduled | Jan 12, 2026Direct / best efforts | |
FHTX: 25 points, Moderate
|
|||||||
| VALNValneva SE | 26 months$122M as of Dec 31, 2025 | Mar 25, 2025max $75M | Jun 4, 2026F-3 | +7% | None scheduled | None in 3 years | |
VALN: 25 points, Moderate
|
|||||||
| SDGRSchrodinger, Inc. | 27 months$366M as of Sep 30, 2026 | Feb 28, 2024max $250Mfiled over 2 years ago | Feb 28, 2024S-3ASR, $250M | n/a | None scheduled | None in 3 years | |
SDGR: 25 points, Moderate
|
|||||||
| DNLIDenali Therapeutics Inc. | 28 months$1.01B as of Sep 30, 2026 | Feb 27, 2025max $400M | Feb 27, 2025S-3ASR, $400M | +9% | None scheduled | Dec 10, 2025Underwritten | |
DNLI: 25 points, Moderate
|
|||||||
| FLNAFILANA THERAPEUTICS, INC. | 28 months$47M as of Sep 30, 2026 | Nov 13, 2025max $50M | Nov 13, 2025S-3, $200M | +4% | None scheduled | None in 3 years | |
FLNA: 25 points, Moderate
|
|||||||
| ALXOALX ONCOLOGY HOLDINGS INC | 29 months$147M as of Sep 30, 2026Offering filed Oct 15, 2026, after this date | Jan 30, 2026size not stated | Mar 6, 2025S-3, $119M | +138% | None scheduled | Oct 15, 2026Private placement | |
ALXO: 25 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CGTXCOGNITION THERAPEUTICS INC | 29 months$31M as of Sep 30, 2026 | Dec 18, 2025max $300M | Dec 18, 2025S-3, $75M | +8% | None scheduled | Aug 28, 2025Direct / best efforts, $6.2M | |
CGTX: 25 points, Moderate
|
|||||||
| PRFXPRF Technologies Ltd. | 31 months$12M as of Dec 31, 2025 | Jan 2, 2025max $4.0M | Sep 20, 2024F-3, $50M | -44% | None scheduled | Oct 16, 2024Underwritten, $4.0M | |
PRFX: 25 points, Moderate
|
|||||||
| PLRXPLIANT THERAPEUTICS, INC. | 33 months$175M as of Sep 30, 2026 | Mar 30, 2026max $50M | Mar 30, 2026S-3 | +1% | None scheduled | None in 3 years | |
PLRX: 25 points, Moderate
|
|||||||
| AUTLAutolus Therapeutics plc | 34 months$248M as of Sep 30, 2026 | None on file | Apr 13, 2026S-3, $150M | +0% | None scheduled | Aug 3, 2026Private placement | |
AUTL: 25 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| BEAMBeam Therapeutics Inc. | 35 months$1.04B as of Sep 30, 2026 | Mar 10, 2025max $236M | Feb 28, 2024S-3ASR, $236M | +2% | None scheduled | Jul 3, 2025Private placement | |
BEAM: 25 points, Moderate
|
|||||||
| FTHFaeth Therapeutics, Inc. | 37 months$175M as of Sep 30, 2026 | Jun 18, 2026max $150M | Jun 18, 2026S-3ASR, $150M | +1,949%split likely, not scored | None scheduled | Feb 18, 2026Private placement | |
FTH: 25 points, Moderate
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| TECXTectonic Therapeutic, Inc. | 39 months$235M as of Sep 30, 2026 | Jul 7, 2025max $100M | Jul 7, 2025S-3, $100M | +7% | None scheduled | Feb 3, 2025Private placement | |
TECX: 25 points, Moderate
|
|||||||
| OKUROnKure Therapeutics, Inc. | 42 months$163M as of Sep 30, 2026 | Aug 4, 2026size not stated | Nov 6, 2025S-3, $16M | n/a | None scheduled | Mar 30, 2026Private placement | |
OKUR: 25 points, Moderate
|
|||||||
| PRTAPROTHENA CORP PUBLIC LTD CO | 44 months$271M as of Sep 30, 2026 | Feb 22, 2024max $250Mfiled over 2 years ago | Feb 22, 2024S-3ASR, $250M | -5% | None scheduled | None in 3 years | |
PRTA: 25 points, Moderate
|
|||||||
| NCNANuCana plc | 46 months$20M as of Dec 31, 2025 | Jun 27, 2025max $100M | Aug 15, 2024F-3, $150M | +14,551%split likely, not scored | None scheduled | May 7, 2025Direct / best efforts | |
NCNA: 25 points, Moderate
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| MBIOMUSTANG BIO, INC. | 47 months$14M as of Sep 30, 2026 | Sep 5, 2025max $4.8M | May 31, 2024S-3, $5.6M | n/a | None scheduled | Feb 7, 2025Direct / best efforts | |
MBIO: 25 points, Moderate
|
|||||||
| NAMSNewAmsterdam Pharma Co N.V. | 49 months$643M as of Sep 30, 2026 | Feb 28, 2025max $250M | Feb 28, 2025S-3 | +6% | None scheduled | Dec 13, 2024Underwritten | |
NAMS: 25 points, Moderate
|
|||||||
| NEUPNeuphoria Therapeutics Inc. | 50 months$19M as of Sep 30, 2026 | Nov 14, 2025size not stated | Nov 18, 2024S-3, $2.0M | +1% | None scheduled | Dec 23, 2024Private placement | |
NEUP: 25 points, Moderate
|
|||||||
| IRLAIRulya Therapeutics Inc. | 52 months$230M as of Sep 30, 2026 | Oct 17, 2025max $69M | Dec 18, 2024S-3, $200M | -81%split likely, not scored | None scheduled | May 18, 2026Private placement | |
IRLA: 25 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| PVLAPALVELLA THERAPEUTICS, INC. | 52 months$237M as of Sep 30, 2026 | None on file | Jan 2, 2026S-3, $300M | +24% | Feb 28, 2027in 102 days | Feb 26, 2026Underwritten | |
PVLA: 25 points, Moderate
|
|||||||
| QNCXIRulya Therapeutics Inc. | 52 months$230M as of Sep 30, 2026 | Oct 17, 2025max $69M | Dec 18, 2024S-3, $200M | -81%split likely, not scored | None scheduled | May 18, 2026Private placement | |
QNCX: 25 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| AVXLANAVEX LIFE SCIENCES CORP. | 52 months$118M as of Jun 30, 2026 | Jul 25, 2025max $150M | Jul 14, 2025S-3 | +8% | None scheduled | None in 3 years | |
AVXL: 25 points, Moderate
|
|||||||
| SMMTSummit Therapeutics Inc. | 52 months$2.63B pro forma for events after Sep 30, 2026 | Jul 23, 2026max $380M | Jun 9, 2026S-3ASR | +7% | None scheduled | Sep 29, 2026Private placement | |
SMMT: 25 points, Moderate
|
|||||||
| NUVBNuvation Bio Inc. | 53 months$726M as of Sep 30, 2026 | Mar 6, 2025max $200M | Mar 6, 2025S-3ASR, $200M | +3% | None scheduled | Jun 29, 2026Convertible | |
NUVB: 25 points, Moderate
|
|||||||
| SBFMSunshine Biopharma Inc. | 54 months$21M pro forma for events after Sep 30, 2026 | Jul 20, 2026max $4.0M | Jan 6, 2025S-3, $100M | -83%split likely, not scored | None scheduled | Oct 9, 2026Direct / best efforts | |
SBFM: 25 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| SNDXSyndax Pharmaceuticals Inc | 58 months$551M as of Sep 30, 2026 | Feb 27, 2024max $157Mfiled over 2 years ago | Feb 27, 2024S-3ASR, $157M | +4% | None scheduled | Jun 10, 2026Private placement | |
SNDX: 25 points, Moderate
|
|||||||
| QUREuniQure N.V. | 60 months$768M as of Sep 30, 2026 | Jul 29, 2025max $200M | Jan 7, 2025S-3ASR | +13% | May 1, 2027in 164 days | Jun 24, 2026Underwritten | |
QURE: 25 points, Moderate
|
|||||||
| CLYMClimb Bio, Inc. | 61 months$228M as of Sep 30, 2026 | Jun 12, 2026max $100M | Nov 5, 2026S-3ASR | -14% | None scheduled | Apr 28, 2026Private placement | |
CLYM: 25 points, Moderate
|
|||||||
| CRSPCRISPR Therapeutics AG | 79 months$2.28B as of Sep 30, 2026 | Oct 15, 2025max $600M | Aug 5, 2024S-3ASR, $379M | +2% | None scheduled | Mar 16, 2026Private placement | |
CRSP: 25 points, Moderate
|
|||||||
| EWTXEdgewise Therapeutics, Inc. | 87 months$1.74B as of Sep 30, 2026 | May 10, 2024max $175Mfiled over 2 years ago | May 10, 2024S-3ASR, $175M | +3% | None scheduled | Apr 2, 2025Underwritten, $200M | |
EWTX: 25 points, Moderate
|
|||||||
| BNTCBenitec Biopharma Inc. | 124 months$176M as of Sep 30, 2026 | Sep 22, 2025max $125M | Sep 14, 2026S-3, $200M | +7% | None scheduled | Nov 7, 2025Direct / best efforts | |
BNTC: 25 points, Moderate
|
|||||||
| RYTMRHYTHM PHARMACEUTICALS, INC. | 158 months$321M as of Sep 30, 2026 | Feb 26, 2026max $200M | Feb 26, 2026S-3ASR, $200M | +4% | None scheduled | Jul 10, 2025Underwritten | |
RYTM: 25 points, Moderate
|
|||||||
| ARDXARDELYX, INC. | 405 months$285M as of Sep 30, 2026 | Nov 3, 2025max $100M | Nov 3, 2025S-3ASR, $100M | +4% | None scheduled | None in 3 years | |
ARDX: 25 points, Moderate
|
|||||||
| JANXJanux Therapeutics, Inc. | 447 months$946M as of Sep 30, 2026 | May 8, 2024max $150Mfiled over 2 years ago | May 8, 2024S-3ASR, $150M | +2% | None scheduled | Dec 5, 2024Underwritten | |
JANX: 25 points, Moderate
|
|||||||
| LGNDLIGAND PHARMACEUTICALS INC | 751 months$447M as of Sep 30, 2026 | Feb 27, 2026max $100M | Feb 27, 2026S-3ASR, $100M | +2% | None scheduled | Jun 25, 2026Private placement | |
LGND: 25 points, Moderate
|
|||||||
| SLNSilence Therapeutics plc | 31 months$72M as of Sep 30, 2026 | Aug 12, 2026size not stated | May 18, 2026S-3, $300M | +32% | None scheduled | None in 3 years | |
SLN: 24 points, Moderate
|
|||||||
| ZBIOZenas BioPharma, Inc. | 34 months$647M as of Sep 30, 2026 | Nov 6, 2026max $200M | Oct 8, 2025S-3ASR, $200M | +26% | May 27, 2027in 190 days | Mar 30, 2026Convertible | |
ZBIO: 24 points, Moderate
|
|||||||
| CAMPCamp4 Therapeutics Corp | 36 months$125M as of Sep 30, 2026 | Dec 1, 2025max $100M | Nov 10, 2025S-3, $100M | +34% | None scheduled | Aug 4, 2026Private placement | |
CAMP: 24 points, Moderate
|
|||||||
| NGNENeurogene Inc. | 41 months$360M as of Sep 30, 2026 | Aug 11, 2025max $150M | Mar 24, 2025S-3, $300M | +34% | None scheduled | Jul 2, 2026Underwritten | |
NGNE: 24 points, Moderate
|
|||||||
| BIOABioAge Labs, Inc. | 42 months$352M as of Sep 30, 2026 | Oct 2, 2025max $250M | Mar 24, 2026S-3ASR | +28% | None scheduled | Jan 22, 2026Underwritten, $115M | |
BIOA: 24 points, Moderate
|
|||||||
| RLAYRelay Therapeutics, Inc. | 43 months$849M as of Sep 30, 2026 | Aug 6, 2026max $213M | Aug 6, 2024S-3ASR, $250M | +28% | None scheduled | Jan 8, 2024Private placement | |
RLAY: 24 points, Moderate
|
|||||||
| EQEquillium, Inc. | 55 months$72M pro forma for events after Sep 30, 2026 | Nov 13, 2025max $75M | Nov 13, 2025S-3, $250M | +35% | None scheduled | Oct 26, 2026Private placement | |
EQ: 24 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CCCCC4 Therapeutics, Inc. | 60 months$275M as of Sep 30, 2026 | Dec 10, 2025max $200M | Nov 21, 2025S-3, $125M | +36% | None scheduled | Oct 16, 2025Underwritten | |
CCCC: 24 points, Moderate
|
|||||||
| TYRATyra Biosciences, Inc. | 66 months$701M as of Sep 30, 2026 | Sep 15, 2026size not stated | Sep 14, 2026S-3ASR | +29% | None scheduled | Oct 18, 2024Private placement | |
TYRA: 24 points, Moderate
|
|||||||
| ENTAENANTA PHARMACEUTICALS INC | 74 months$211M as of Jun 30, 2026 | Jul 2, 2026max $75M | Feb 11, 2026S-3, $150M | +36% | None scheduled | Oct 1, 2025Underwritten, $65M | |
ENTA: 24 points, Moderate
|
|||||||
| DNTHDianthus Therapeutics, Inc. /DE/ | 75 months$1.24B as of Sep 30, 2026 | Sep 18, 2026max $500M | Sep 18, 2026S-3ASR, $500M | +31% | None scheduled | Mar 11, 2026Underwritten | |
DNTH: 24 points, Moderate
|
|||||||
| GRMLGreenland Mines Ltd | 20 months$57M as of Sep 30, 2026Offering filed Nov 12, 2026, after this date | Sep 23, 2026size not stated | Jul 7, 2025S-3, $50M | -80%split likely, not scored | None scheduled | Nov 12, 2026Private placement | |
GRML: 23 points, Moderate
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CPHICHINA PHARMA HOLDINGS, INC. | 21 months$0.3M as of Jun 30, 2026Offering filed Jul 23, 2026, after this date | Dec 13, 2024size not stated | Jan 12, 2024S-3 | +1,219%split likely, not scored | None scheduled | Jul 23, 2026Underwritten | |
CPHI: 23 points, Moderate
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| EMISEmmis Acquisition Corp. | 21 months$0.7M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Sep 29, 2025Private placement | |
EMIS: 23 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| VOGXVogenx, Inc. | 179 months$82M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Aug 12, 2026Underwritten, $81M | |
VOGX: 23 points, Moderate
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| RCUSArcus Biosciences, Inc. | 20 months$694M as of Sep 30, 2026Offering filed Oct 22, 2026, after this date | Feb 25, 2026max $200M | Feb 25, 2026S-3ASR, $200M | +33% | None scheduled | Oct 22, 2026Underwritten, $250M | |
RCUS: 22 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| XFORX4 Pharmaceuticals, Inc | 28 months$188M as of Sep 30, 2026Offering filed Oct 8, 2026, after this date | May 6, 2026max $75M | May 6, 2026S-3, $300M | +17% | None scheduled | Oct 8, 2026Private placement | |
XFOR: 22 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PCVXVaxcyte, Inc. | 30 months$2.26B as of Sep 30, 2026Offering filed Oct 8, 2026, after this date | Feb 24, 2026max $500M | May 24, 2024S-3ASR, $400M | +21% | None scheduled | Oct 8, 2026Convertible | |
PCVX: 22 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| TSHATaysha Gene Therapies, Inc. | 35 months$423M as of Sep 30, 2026 | Nov 4, 2025max $212M | Nov 4, 2025S-3ASR, $200M | +19% | None scheduled | Jun 25, 2026Underwritten | |
TSHA: 22 points, Moderate
|
|||||||
| MGTXMeiraGTx Holdings plc | 41 months$143M as of Sep 30, 2026 | Nov 12, 2026max $100M | Nov 12, 2026S-3ASR, $100M | +21% | None scheduled | Jul 7, 2026Private placement | |
MGTX: 22 points, Moderate
|
|||||||
| MAZEMaze Therapeutics, Inc. | 60 months$477M as of Sep 30, 2026Offering filed Oct 16, 2026, after this date | Apr 22, 2026size not stated | Feb 4, 2026S-3ASR, $200M | +14% | None scheduled | Oct 16, 2026Private placement | |
MAZE: 22 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| IFRXInflaRx N.V. | 80 months$159M as of Dec 31, 2025Offering filed May 7, 2026, after this date | Aug 14, 2026max $65M | Aug 6, 2026F-3 | +22% | None scheduled | May 7, 2026Underwritten, $150M | |
IFRX: 22 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| GHRSGH Research PLC | 84 months$363M as of Dec 31, 2025Offering filed Apr 29, 2026, after this date | May 14, 2026max $200M | May 14, 2026F-3, $400M | +19% | None scheduled | Apr 29, 2026Underwritten | |
GHRS: 22 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| BLRXBioLineRx Ltd. | n/aOffering filed Aug 31, 2026, after this date | Jul 25, 2025max $4.9M | Dec 29, 2023F-3, $250M | +17% | None scheduled | Aug 31, 2026Direct / best efforts | |
BLRX: 22 points, Moderate
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MLTXMoonLake Immunotherapeutics | 25 months$498M as of Sep 30, 2026 | Aug 10, 2026max $300M | Aug 10, 2026S-3ASR, $300M | n/a | None scheduled | None in 3 years | |
MLTX: 20 points, Moderate
|
|||||||
| KURAKura Oncology, Inc. | 25 months$492M as of Sep 30, 2026 | Nov 10, 2026max $150M | Nov 10, 2026S-3ASR, $150M | +6% | None scheduled | Jan 26, 2024Private placement | |
KURA: 20 points, Moderate
|
|||||||
| CMPXCompass Therapeutics, Inc. | 32 months$163M as of Sep 30, 2026 | Dec 30, 2025max $100M | Dec 30, 2025S-3, $100M | +1% | None scheduled | Aug 13, 2025Underwritten | |
CMPX: 20 points, Moderate
|
|||||||
| PMCBPharmaCyte Biotech, Inc. | 49 months$18M as of Jul 31, 2026 | None on file | None | +58% | None scheduled | Aug 18, 2025Private placement | |
PMCB: 20 points, Moderate
|
|||||||
| CLLSCellectis S.A. | No operating burn$147M as of Dec 31, 2025 | None on file | Jul 2, 2025F-3, $200M | +57% | None scheduled | None in 3 years | |
CLLS: 20 points, Moderate
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| MGNXMACROGENICS INC | 14 months$173M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
MGNX: 18 points, Low
|
|||||||
| HELPHelus Pharma Inc. | 14 months$166M as of Mar 31, 2026 | None on file | None | -97%split likely, not scored | None scheduled | None in 3 years | |
HELP: 18 points, Low
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| RZLTRezolute, Inc. | 17 months$90M as of Sep 30, 2026Offering filed Nov 16, 2026, after this date | None on file | Nov 5, 2026S-3 | +4% | None scheduled | Nov 16, 2026Underwritten | |
RZLT: 18 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| NNNNAnbio Biotechnology | 21 months$12M as of Dec 31, 2025 | None on file | Jul 9, 2026F-3ASR | n/a | None scheduled | Feb 19, 2025Underwritten | |
NNNN: 18 points, Low
|
|||||||
| PEPGPepGen Inc. | 22 months$105M as of Sep 30, 2026Offering filed Nov 12, 2026, after this date | May 18, 2026max $100M | May 18, 2026S-3, $100M | +1% | None scheduled | Nov 12, 2026Underwritten, $125M | |
PEPG: 18 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| YARWYarrow Bioscience, Inc. | 23 months$23M as of Sep 30, 2026 | Sep 11, 2026max $50M | Mar 1, 2024S-3, $50M | n/a | None scheduled | Jul 28, 2026Private placement | |
YARW: 18 points, Low
|
|||||||
| XBIOXenetic Biosciences, Inc. | 23 months$5.8M as of Sep 30, 2026 | None on file | Oct 21, 2024S-3 | +2% | None scheduled | Sep 16, 2026Private placement | |
XBIO: 18 points, Low
|
|||||||
| BCAXBicara Therapeutics Inc. | 27 months$442M as of Sep 30, 2026 | Nov 26, 2025max $150M | Oct 3, 2025S-3, $150M | +21% | None scheduled | Feb 26, 2026Underwritten | |
BCAX: 17 points, Low
|
|||||||
| CLDXCelldex Therapeutics, Inc. | 32 months$650M as of Sep 30, 2026 | Feb 26, 2024max $300Mfiled over 2 years ago | Nov 5, 2026S-3ASR | +18% | None scheduled | Apr 2, 2026Underwritten | |
CLDX: 17 points, Low
|
|||||||
| PALIPALISADE BIO, INC. | 35 months$114M as of Sep 30, 2026 | None on file | May 12, 2026S-3 | +20% | None scheduled | Oct 2, 2025Underwritten | |
PALI: 17 points, Low
|
|||||||
| TRVITrevi Therapeutics, Inc. | 48 months$299M as of Sep 30, 2026 | Nov 13, 2025max $200M | Nov 13, 2025S-3ASR | +11% | None scheduled | Apr 17, 2026Underwritten, $151M | |
TRVI: 17 points, Low
|
|||||||
| MBXMBX Biosciences, Inc. | 50 months$483M as of Sep 30, 2026 | Mar 12, 2026max $250M | Mar 12, 2026S-3ASR, $250M | +11% | None scheduled | Sep 25, 2025Underwritten, $200M | |
MBX: 17 points, Low
|
|||||||
| SYRESpyre Therapeutics, Inc. | 61 months$1.50B pro forma for events after Sep 30, 2026 | Jun 26, 2026max $500M | Jun 26, 2026S-3ASR, $500M | +22% | None scheduled | Oct 6, 2026Underwritten, $350M | |
SYRE: 17 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| AMLXAmylyx Pharmaceuticals, Inc. | 71 months$768M as of Sep 30, 2026 | None on file | Mar 3, 2026S-3ASR | +17% | None scheduled | Aug 20, 2026Underwritten, $500M | |
AMLX: 17 points, Low
|
|||||||
| KYMRKymera Therapeutics, Inc. | 75 months$1.65B as of Sep 30, 2026 | Feb 26, 2026max $500M | Oct 31, 2024S-3ASR, $300M | +19% | None scheduled | Dec 10, 2025Underwritten, $602M | |
KYMR: 17 points, Low
|
|||||||
| ELVNEnliven Therapeutics, Inc. | 171 months$884M as of Sep 30, 2026 | Jun 12, 2026size not stated | Aug 13, 2025S-3ASR, $200M | +24% | None scheduled | Jun 16, 2025Underwritten | |
ELVN: 17 points, Low
|
|||||||
| BBTXBambusa Therapeutics, Inc. | 21 months$71M | None on file | None | n/a | None scheduled | Oct 30, 2026Underwritten, $169M | |
BBTX: 16 points, Low
|
|||||||
| KTTAPasithea Therapeutics Corp. | 27 months$41M as of Sep 30, 2026 | Jun 20, 2025max $4.2M | None | +394%split likely, not scored | None scheduled | Dec 2, 2025Private placement | |
KTTA: 15 points, Low
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| ORICOric Pharmaceuticals, Inc. | 28 months$345M as of Sep 30, 2026 | Feb 23, 2026max $200M | Mar 11, 2024S-3ASR, $200M | +7% | None scheduled | May 28, 2025Private placement | |
ORIC: 15 points, Low
|
|||||||
| IMRXImmuneering Corp | 30 months$166M as of Sep 30, 2026 | Aug 13, 2025max $100M | Aug 13, 2025S-3, $300M | n/a | None scheduled | Sep 25, 2025Underwritten | |
IMRX: 15 points, Low
|
|||||||
| ABEOABEONA THERAPEUTICS INC. | 31 months$135M as of Sep 30, 2026Offering filed Nov 9, 2026, after this date | Jun 21, 2024max $75Mfiled over 2 years ago | Jun 12, 2024S-3, $75M | +6% | None scheduled | Nov 9, 2026Private placement | |
ABEO: 15 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| SILOSilo Pharma, Inc. | 35 months$8.1M as of Sep 30, 2026Offering filed Nov 6, 2026, after this date | None on file | Jan 23, 2024S-3 | -84%split likely, not scored | None scheduled | Nov 6, 2026Private placement | |
SILO: 15 points, Low
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| BDTXBlack Diamond Therapeutics, Inc. | 38 months$102M as of Sep 30, 2026 | Nov 13, 2025max $150M | Nov 13, 2025S-3, $500M | +1% | None scheduled | None in 3 years | |
BDTX: 15 points, Low
|
|||||||
| ARCTArcturus Therapeutics Holdings Inc. | 41 months$185M as of Sep 30, 2026Offering filed Nov 16, 2026, after this date | Dec 30, 2025max $188M | Dec 30, 2025S-3, $500M | +1% | None scheduled | Nov 16, 2026Private placement | |
ARCT: 15 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ENSCEnsysce Biosciences, Inc. | 53 months$30M as of Sep 30, 2026 | None on file | None | +449%split likely, not scored | None scheduled | Aug 6, 2026Private placement | |
ENSC: 15 points, Low
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| ARVNARVINAS, INC. | 57 months$558M as of Sep 30, 2026 | Nov 3, 2026max $200M | Nov 3, 2026S-3, $200M | +2% | None scheduled | Nov 27, 2023Private placement | |
ARVN: 15 points, Low
|
|||||||
| ADAGAdagene Inc. | 80 months$128M as of Dec 31, 2025Offering filed Apr 2, 2026, after this date | May 30, 2025size not stated | May 9, 2025F-3 | +1% | None scheduled | Apr 2, 2026Underwritten | |
ADAG: 15 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| KROSKeros Therapeutics, Inc. | 91 months$259M as of Sep 30, 2026 | Sep 10, 2026max $100M | Sep 10, 2026S-3, $350M | -36% | None scheduled | Jan 4, 2024Underwritten, $140M | |
KROS: 15 points, Low
|
|||||||
| DRUGBRIGHT MINDS BIOSCIENCES INC. | 150 months$308M as of Sep 30, 2025Offering filed Jan 9, 2026, after this date | Aug 26, 2025max $100M | Aug 26, 2025F-3, $100M | +1% | None scheduled | Jan 9, 2026Underwritten | |
DRUG: 15 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CORTCORCEPT THERAPEUTICS INC | No operating burn$662M as of Sep 30, 2026 | None on file | None | +4% | Dec 17, 2026in 29 days | None in 3 years | |
CORT: 15 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| GILDGILEAD SCIENCES, INC. | No operating burn$6.44B as of Sep 30, 2026 | None on file | Aug 6, 2026S-3ASR | 0% | Dec 23, 2026in 35 days | None in 3 years | |
GILD: 15 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| GELSGelteq Ltd | n/a | None on file | None | n/a | None scheduled | None in 3 years | |
GELS: 15 points, Low
The latest 10-Q or 10-K states substantial doubt about the company's ability to continue as a going concern: a raise is usually close. |
|||||||
| PHARPharming Group N.V. | No operating burn$190M as of Dec 31, 2025 | None on file | None | +3% | Jan 30, 2027in 73 days | None in 3 years | |
PHAR: 15 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| IMRNImmuron Ltd | 33 months$9.0M as of Jun 30, 2026Offering filed Oct 23, 2026, after this date | None on file | Jul 3, 2024F-3, $15M | +38% | None scheduled | Oct 23, 2026Underwritten | |
IMRN: 14 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| EPRXEUPRAXIA PHARMACEUTICALS INC. | 34 months$126M as of Dec 31, 2025 | None on file | None | +31% | None scheduled | None in 3 years | |
EPRX: 14 points, Low
|
|||||||
| NRIXNurix Therapeutics, Inc. | No operating burn$1.06B as of Aug 31, 2026 | Mar 6, 2026max $414M | Jun 11, 2024S-3ASR | +42% | None scheduled | Apr 12, 2024Underwritten | |
NRIX: 14 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| AXGNAxogen, Inc. | No operating burn$348M as of Sep 30, 2026 | None on file | Jan 21, 2026S-3ASR | +30% | None scheduled | Sep 10, 2026Underwritten, $209M | |
AXGN: 14 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ZURAZura Bio Ltd | No operating burn$188M as of Sep 30, 2026 | Oct 27, 2026max $114M | Oct 27, 2026S-3, $700M | +48% | None scheduled | Feb 25, 2026Underwritten | |
ZURA: 14 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| FENCFENNEC PHARMACEUTICALS INC. | No operating burn$49M as of Sep 30, 2026 | None on file | None | +26% | None scheduled | Nov 18, 2025Direct / best efforts, $5.0M | |
FENC: 14 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| IMMPIMMUTEP Ltd | 15 months$69M as of Jun 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
IMMP: 13 points, Low
|
|||||||
| RCKTROCKET PHARMACEUTICALS, INC. | 21 months$270M as of Sep 30, 2026Offering filed Oct 6, 2026, after this date | Mar 10, 2026max $100M | Mar 2, 2026S-3 | +3% | None scheduled | Oct 6, 2026Private placement | |
RCKT: 13 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| OCULOCULAR THERAPEUTIX, INC | 24 months$531M as of Sep 30, 2026 | None on file | Sep 30, 2025S-3ASR | +3% | None scheduled | Sep 30, 2025Underwritten | |
OCUL: 13 points, Low
|
|||||||
| EIKNEikon Therapeutics, Inc. | 21 months$462M as of Jun 30, 2026 | None on file | None | n/a | None scheduled | Feb 5, 2026Underwritten, $381M | |
EIKN: 11 points, Low
|
|||||||
| GENBGenerate Biomedicines, Inc. | 22 months$404M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Feb 27, 2026Underwritten, $400M | |
GENB: 11 points, Low
|
|||||||
| GRCEGrace Therapeutics, Inc. | 26 months$21M as of Jun 30, 2026Offering filed Aug 6, 2026, after this date | None on file | None | +52% | None scheduled | Aug 6, 2026Private placement | |
GRCE: 10 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| DERMJourney Medical Corp | 26 months$22M as of Sep 30, 2026 | None on file | Jan 15, 2026S-3, $150M | n/a | None scheduled | None in 3 years | |
DERM: 10 points, Low
|
|||||||
| BBOTBridgeBio Oncology Therapeutics, Inc. | 26 months$315M as of Sep 30, 2026 | Sep 1, 2026max $200M | Sep 1, 2026S-3, $200M | +0% | None scheduled | Aug 13, 2025Private placement | |
BBOT: 10 points, Low
|
|||||||
| ALDXAldeyra Therapeutics, Inc. | 28 months$41M as of Sep 30, 2026 | Aug 1, 2024max $75Mfiled over 2 years ago | Mar 7, 2024S-3, $200M | +0% | None scheduled | None in 3 years | |
ALDX: 10 points, Low
|
|||||||
| MESOMESOBLAST LTD | 28 months$103M as of Jun 30, 2026 | None on file | Dec 31, 2025F-3ASR | +1% | None scheduled | None in 3 years | |
MESO: 10 points, Low
|
|||||||
| UPCUniverse Pharmaceuticals INC | 29 months$29M as of Sep 30, 2025 | None on file | Sep 29, 2026F-3, $200M | -98%split likely, not scored | None scheduled | Dec 9, 2024Direct / best efforts | |
UPC: 10 points, Low
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| BCYCBICYCLE THERAPEUTICS PLC | 31 months$470M as of Sep 30, 2026 | None on file | Aug 8, 2025S-3, $500M | +1% | None scheduled | May 23, 2024Private placement | |
BCYC: 10 points, Low
|
|||||||
| MPLTMapLight Therapeutics, Inc. | 32 months$463M as of Sep 30, 2026 | Nov 16, 2026max $100M | Nov 16, 2026S-3, $400M | n/a | None scheduled | Aug 13, 2026Private placement | |
MPLT: 10 points, Low
|
|||||||
| CELCCelcuity Inc. | 32 months$643M as of Sep 30, 2026 | Jan 9, 2026max $400M | Jan 9, 2026S-3ASR, $400M | +6% | None scheduled | Jun 5, 2026Convertible | |
CELC: 10 points, Low
|
|||||||
| SIONSionna Therapeutics, Inc. | 37 months$250M as of Sep 30, 2026 | Mar 2, 2026max $250M | Mar 2, 2026S-3ASR, $250M | +1% | None scheduled | Feb 7, 2025Underwritten, $191M | |
SION: 10 points, Low
|
|||||||
| MYGNMYRIAD GENETICS INC | 43 months$107M as of Sep 30, 2026 | None on file | Feb 24, 2026S-3 | +3% | None scheduled | None in 3 years | |
MYGN: 10 points, Low
|
|||||||
| EOLSEvolus, Inc. | 45 months$42M as of Sep 30, 2026 | None on file | Jun 5, 2026S-3, $250M | +2% | None scheduled | Mar 11, 2024Underwritten, $50M | |
EOLS: 10 points, Low
|
|||||||
| AGIOAGIOS PHARMACEUTICALS, INC. | 47 months$907M as of Sep 30, 2026 | None on file | Feb 12, 2026S-3ASR | +3% | None scheduled | None in 3 years | |
AGIO: 10 points, Low
|
|||||||
| HRTXHERON THERAPEUTICS, INC. /DE/ | 47 months$23M as of Sep 30, 2026 | None on file | Sep 9, 2025S-3 | +4% | None scheduled | Aug 8, 2025Private placement | |
HRTX: 10 points, Low
|
|||||||
| PGENPRECIGEN, INC. | 52 months$51M as of Sep 30, 2026 | None on file | Dec 29, 2023S-3, $300M | +1% | None scheduled | Sep 17, 2025Private placement | |
PGEN: 10 points, Low
|
|||||||
| KRSAKorsana Biosciences, Inc. | 57 months$456M as of Sep 30, 2026 | May 7, 2025max $20M | Feb 4, 2025S-3 | +1,060%split likely, not scored | None scheduled | Sep 11, 2026Private placement | |
KRSA: 10 points, Low
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| XNCRXencor Inc | 63 months$556M as of Sep 30, 2026 | None on file | Feb 25, 2026S-3ASR | +5% | None scheduled | Sep 12, 2024Underwritten | |
XNCR: 10 points, Low
|
|||||||
| MNPRMonopar Therapeutics | 82 months$129M as of Sep 30, 2026 | None on file | Aug 29, 2025S-3, $300M | +1% | None scheduled | Sep 24, 2025Underwritten | |
MNPR: 10 points, Low
|
|||||||
| ANLAdlai Nortye Group Ltd. | 83 months$233M as of Dec 31, 2025 | None on file | Mar 10, 2026F-3 | n/a | None scheduled | None in 3 years | |
ANL: 10 points, Low
|
|||||||
| SEPNSepterna, Inc. | 94 months$565M as of Sep 30, 2026 | Mar 10, 2026max $150M | Mar 10, 2026S-3ASR, $150M | +6% | None scheduled | Oct 25, 2024Underwritten, $288M | |
SEPN: 10 points, Low
|
|||||||
| TLXTelix Pharmaceuticals Ltd | 252 months$252M as of Dec 31, 2025 | None on file | Feb 20, 2026F-3ASR | +1% | None scheduled | None in 3 years | |
TLX: 10 points, Low
|
|||||||
| AYTUAYTU BIOPHARMA, INC | 280 months$25M as of Sep 30, 2026 | None on file | Sep 26, 2024S-3 | +7% | None scheduled | Apr 2, 2026Private placement | |
AYTU: 10 points, Low
|
|||||||
| BGMBGM Group Ltd. | n/a | None on file | Apr 10, 2024F-3, $200M | 0% | None scheduled | None in 3 years | |
BGM: 10 points, Low
|
|||||||
| ASBPAspire-Lakewood Holdings, Inc. | 14 months$12M as of Jun 30, 2026Offering filed Aug 10, 2026, after this date | None on file | None | -97%split likely, not scored | None scheduled | Aug 10, 2026Private placement | |
ASBP: 8 points, Low
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ATNMActinium Pharmaceuticals, Inc. | 20 months$36M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
ATNM: 8 points, Low
|
|||||||
| ATHEALTERITY THERAPEUTICS LTD | 20 months$37M as of Jun 30, 2026 | None on file | None | -98%split likely, not scored | None scheduled | Feb 15, 2024Direct / best efforts | |
ATHE: 8 points, Low
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| RAREUltragenyx Pharmaceutical Inc. | 20 months$467M as of Sep 30, 2026 | None on file | None | +6% | None scheduled | None in 3 years | |
RARE: 8 points, Low
|
|||||||
| SCNIScinai Immunotherapeutics Ltd. | 21 months$15M pro forma for events after Dec 31, 2025 | None on file | None | +307%split likely, not scored | None scheduled | None in 3 years | |
SCNI: 8 points, Low
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| NVAXNOVAVAX INC | 22 months$622M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | Aug 27, 2025Private placement | |
NVAX: 8 points, Low
|
|||||||
| MRNAModerna, Inc. | 23 months$7.98B as of Sep 30, 2026 | None on file | None | +4% | None scheduled | Sep 1, 2026Private placement | |
MRNA: 8 points, Low
|
|||||||
| CTYCITY THERAPEUTICS, INC. | 26 months$170M | None on file | None | n/a | None scheduled | Oct 16, 2026Underwritten | |
CTY: 8 points, Low
|
|||||||
| KARDKardigan, Inc. | 33 months$591M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Jun 18, 2026Underwritten, $400M | |
KARD: 8 points, Low
|
|||||||
| ELOXEloxx Pharmaceuticals, Inc. | 36 months$62M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Jun 9, 2026Underwritten | |
ELOX: 8 points, Low
|
|||||||
| IAMIambic Therapeutics, Inc. | 38 months$208M | None on file | None | n/a | None scheduled | Oct 15, 2026Underwritten, $150M | |
IAM: 8 points, Low
|
|||||||
| LYCALycia Therapeutics, Inc. | 44 months$124M | None on file | None | n/a | None scheduled | Oct 23, 2026Underwritten, $318M | |
LYCA: 8 points, Low
|
|||||||
| ARGXARGENX SE | No operating burn$5.18B as of Dec 31, 2025 | None on file | None | +2% | Feb 18, 2027in 92 days | None in 3 years | |
ARGX: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| BMRNBIOMARIN PHARMACEUTICAL INC | No operating burn$1.47B as of Sep 30, 2026 | None on file | None | +1% | Feb 28, 2027in 102 days | None in 3 years | |
BMRN: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| APMDApnimed, Inc. | No operating burn$173M as of Sep 30, 2026 | None on file | None | n/a | Feb 28, 2027in 102 days | Jul 31, 2026Underwritten, $192M | |
APMD: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ARQTArcutis Biotherapeutics, Inc. | No operating burn$259M as of Sep 30, 2026 | Nov 4, 2026max $200M | Feb 25, 2026S-3ASR | +3% | Feb 23, 2027in 97 days | Mar 1, 2024Underwritten, $150M | |
ARQT: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ETONEton Pharmaceuticals, Inc. | No operating burn$56M as of Sep 30, 2026 | None on file | None | +8% | Mar 29, 2027in 131 days | Dec 12, 2024Direct / best efforts | |
ETON: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| HRMYHarmony Biosciences Holdings, Inc. | No operating burn$771M as of Sep 30, 2026 | Feb 25, 2025max $200M | Feb 25, 2025S-3ASR, $200M | +2% | Apr 1, 2027in 134 days | None in 3 years | |
HRMY: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| JAZZJazz Pharmaceuticals plc | No operating burn$2.86B as of Sep 30, 2026 | None on file | None | +6% | Apr 16, 2027in 149 days | Aug 31, 2026Private placement | |
JAZZ: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| BMYBRISTOL MYERS SQUIBB CO | No operating burn$12.96B as of Sep 30, 2026 | None on file | Dec 13, 2024S-3ASR | +0% | May 13, 2027in 176 days | None in 3 years | |
BMY: 8 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| LBRXLB PHARMACEUTICALS INC | 24 months$404M as of Sep 30, 2026 | None on file | None | +28% | None scheduled | Jul 29, 2026Private placement | |
LBRX: 7 points, Low
|
|||||||
| ABVXAbivax S.A. | 25 months$402M as of Dec 31, 2025Offering filed Jul 2, 2026, after this date | None on file | Jul 23, 2025F-3ASR | +24% | None scheduled | Jul 2, 2026Underwritten, $800M | |
ABVX: 7 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| RAPPRapport Therapeutics, Inc. | 29 months$395M as of Sep 30, 2026Offering filed Oct 30, 2026, after this date | Mar 10, 2026max $150M | Mar 10, 2026S-3ASR, $150M | +24% | None scheduled | Oct 30, 2026Convertible | |
RAPP: 7 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ADCTADC Therapeutics SA | 29 months$189M as of Sep 30, 2026Offering filed Oct 13, 2026, after this date | None on file | Aug 6, 2024S-3, $300M | +14% | None scheduled | Oct 13, 2026Private placement | |
ADCT: 7 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| IRONDisc Medicine, Inc. | 49 months$683M as of Sep 30, 2026Offering filed Oct 21, 2026, after this date | Nov 5, 2026max $190M | Aug 8, 2024S-3ASR | +21% | None scheduled | Oct 21, 2026Underwritten, $450M | |
IRON: 7 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| TKNOAlpha Teknova, Inc. | 57 months$17M as of Sep 30, 2026Offering filed Oct 21, 2026, after this date | None on file | Jul 10, 2025S-3, $225M | +18% | None scheduled | Oct 21, 2026Underwritten, $40M | |
TKNO: 7 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| BCRXBIOCRYST PHARMACEUTICALS INC | No operating burn$375M as of Sep 30, 2026 | None on file | Feb 27, 2024S-3ASR | +22% | None scheduled | None in 3 years | |
BCRX: 7 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CELUCelularity Inc | No operating burn$0.6M as of Jun 30, 2026 | None on file | None | +15% | None scheduled | Sep 28, 2026Private placement | |
CELU: 7 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| XERSXeris Biopharma Holdings, Inc. | No operating burn$131M as of Sep 30, 2026 | None on file | Mar 6, 2025S-3, $250M | +10% | None scheduled | Jul 17, 2026Private placement | |
XERS: 7 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| AMRXAmneal Pharmaceuticals, Inc. | No operating burn$157M as of Sep 30, 2026 | None on file | None | +11% | None scheduled | Aug 10, 2026Private placement | |
AMRX: 7 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| RGENREPLIGEN CORP | No operating burn$863M as of Sep 30, 2026 | None on file | None | +14% | None scheduled | Nov 6, 2026Private placement | |
RGEN: 7 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| TARSTarsus Pharmaceuticals, Inc. | No operating burn$310M as of Sep 30, 2026 | Mar 13, 2025size not stated | Feb 29, 2024S-3ASR | +16% | None scheduled | Aug 6, 2026Private placement | |
TARS: 7 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| VIRVir Biotechnology, Inc. | No operating burn$455M as of Sep 30, 2026 | None on file | Nov 12, 2026S-3ASR | +23% | None scheduled | Nov 16, 2026Underwritten, $150M | |
VIR: 7 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| TRAXFirst Tracks Biotherapeutics, Inc. | 19 months$156M as of Sep 30, 2026Offering filed Oct 15, 2026, after this date | None on file | None | n/a | None scheduled | Oct 15, 2026Private placement | |
TRAX: 6 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| MNOVMEDICINOVA INC | 41 months$29M as of Sep 30, 2026 | None on file | Dec 5, 2025S-3, $300M | +5% | None scheduled | Dec 30, 2025Direct / best efforts | |
MNOV: 5 points, Low
|
|||||||
| KLRAKailera Therapeutics, Inc. | 30 months$1.04B as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Apr 17, 2026Underwritten, $625M | |
KLRA: 3 points, Low
|
|||||||
| BLSMBlossomHill Therapeutics, Inc. | 40 months$225M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Aug 7, 2026Underwritten, $150M | |
BLSM: 3 points, Low
|
|||||||
| GPCRStructure Therapeutics Inc. | 34 months$1.24B as of Sep 30, 2026 | None on file | Aug 6, 2025S-3ASR, $250M | +18% | None scheduled | Dec 10, 2025Underwritten | |
GPCR: 2 points, Low
|
|||||||
| TRXBTRex Bio, Inc. | 24 months$91M as of Sep 30, 2026Offering filed Oct 9, 2026, after this date | None on file | None | n/a | None scheduled | Oct 9, 2026Underwritten, $117M | |
TRXB: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| HROWHARROW, INC. | 25 months$75M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | Nov 18, 2025Private placement | |
HROW: 0 points, Low
|
|||||||
| MSLESatellos Bioscience Inc. | 26 months$62M as of Dec 31, 2025 | None on file | None | n/a | None scheduled | None in 3 years | |
MSLE: 0 points, Low
|
|||||||
| TENXTENAX THERAPEUTICS, INC. | 26 months$114M as of Sep 30, 2026 | None on file | Mar 24, 2026S-3, $300M | +629%split likely, not scored | None scheduled | Mar 6, 2025Private placement | |
TENX: 0 points, Low
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| CSBRCHAMPIONS ONCOLOGY, INC. | 27 months$4.4M as of Jul 31, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
CSBR: 0 points, Low
|
|||||||
| CMNDClearmind Medicine Inc. | 27 months$16M as of Oct 31, 2025Offering filed Dec 3, 2025, after this date | None on file | Apr 30, 2026F-3 | n/a | None scheduled | Dec 3, 2025Direct / best efforts | |
CMND: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| PRQRProQR Therapeutics N.V. | 29 months$117M as of Dec 31, 2025Offering filed Jun 26, 2026, after this date | None on file | Sep 30, 2024F-3 | +0% | None scheduled | Jun 26, 2026Underwritten | |
PRQR: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| OPKOPKO HEALTH, INC. | 29 months$384M as of Sep 30, 2026 | None on file | None | -3% | None scheduled | Apr 1, 2025Private placement | |
OPK: 0 points, Low
|
|||||||
| OPTHOptimi Health Corp. | 30 months$13M | None on file | None | n/a | None scheduled | May 20, 2026Underwritten | |
OPTH: 0 points, Low
|
|||||||
| ODTXOdyssey Therapeutics, Inc. | 31 months$387M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | May 11, 2026Private placement | |
ODTX: 0 points, Low
|
|||||||
| EVMNEvommune, Inc. | 34 months$262M as of Jun 30, 2026Offering filed Nov 4, 2026, after this date | None on file | None | n/a | None scheduled | Nov 4, 2026Private placement | |
EVMN: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| SPTXSeaport Therapeutics, Inc. | 36 months$290M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | May 1, 2026Underwritten, $255M | |
SPTX: 0 points, Low
|
|||||||
| NBTXNanobiotix S.A. | 39 months$111M as of Dec 31, 2025Offering filed May 22, 2026, after this date | None on file | Mar 6, 2025F-3, $200M | +2% | None scheduled | May 22, 2026Underwritten | |
NBTX: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| NGENNERVGEN PHARMA CORP. | 41 months$87M as of Dec 31, 2025 | None on file | None | n/a | None scheduled | None in 3 years | |
NGEN: 0 points, Low
|
|||||||
| AVLNAvalyn Pharma Inc. | 44 months$387M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Apr 30, 2026Underwritten, $300M | |
AVLN: 0 points, Low
|
|||||||
| SCTXScribe Therapeutics, Inc. | 46 months$174M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Jul 27, 2026Underwritten, $129M | |
SCTX: 0 points, Low
|
|||||||
| VORVor Biopharma Inc. | 50 months$482M as of Sep 30, 2026Offering filed Nov 12, 2026, after this date | Oct 30, 2026max $150M | Sep 4, 2026S-3ASR | +490%split likely, not scored | None scheduled | Nov 12, 2026Private placement | |
VOR: 0 points, Low
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| COAGHemab Therapeutics Holdings, Inc. | 52 months$442M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | May 1, 2026Underwritten, $302M | |
COAG: 0 points, Low
|
|||||||
| EVOEvotec SE | 53 months$401M as of Dec 31, 2025 | None on file | None | +0% | None scheduled | None in 3 years | |
EVO: 0 points, Low
|
|||||||
| AGMBAgomAb Therapeutics NV | 53 months$252M as of Dec 31, 2025Offering filed Feb 6, 2026, after this date | None on file | None | n/a | None scheduled | Feb 6, 2026Underwritten | |
AGMB: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| ATTOAttovia Therapeutics, Inc. | 58 months$396M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Aug 5, 2026Underwritten, $289M | |
ATTO: 0 points, Low
|
|||||||
| RNAAtrium Therapeutics, Inc. | 60 months$294M pro forma for events after Sep 30, 2026 | None on file | None | n/a | None scheduled | Oct 8, 2026Private placement | |
RNA: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| LTGOLatigo Biotherapeutics, Inc. | 61 months$401M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Aug 7, 2026Underwritten, $346M | |
LTGO: 0 points, Low
|
|||||||
| AKTSAktis Oncology, Inc. | 63 months$493M as of Jun 30, 2026 | None on file | None | n/a | None scheduled | Jan 9, 2026Underwritten, $318M | |
AKTS: 0 points, Low
|
|||||||
| LEGNLegend Biotech Corp | 66 months$852M as of Dec 31, 2025Offering filed Jun 18, 2026, after this date | None on file | Mar 19, 2024F-3ASR | +1% | None scheduled | Jun 18, 2026Underwritten | |
LEGN: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| SLGLSol-Gel Technologies Ltd. | 67 months$48M as of Dec 31, 2025Offering filed Mar 24, 2026, after this date | None on file | Apr 29, 2025F-3, $120M | -90%split likely, not scored | None scheduled | Mar 24, 2026Underwritten, $33M | |
SLGL: 0 points, Low
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| XBITXBiotech Inc. | 70 months$105M as of Sep 30, 2026 | None on file | None | 0% | None scheduled | Jan 4, 2024Private placement | |
XBIT: 0 points, Low
|
|||||||
| MXCTMAXCYTE, INC. | 78 months$133M pro forma for events after Sep 30, 2026 | None on file | None | -3% | None scheduled | Nov 10, 2026Private placement | |
MXCT: 0 points, Low
An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| DMRADamora Therapeutics, Inc. | 81 months$528M as of Sep 30, 2026 | None on file | Feb 10, 2026S-3ASR, $150M | +4,564%split likely, not scored | None scheduled | Feb 11, 2026Underwritten, $275M | |
DMRA: 0 points, Low
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| LKFTLakefront Biotherapeutics NV | 118 months$2.24B as of Dec 31, 2025 | None on file | None | 0% | None scheduled | None in 3 years | |
LKFT: 0 points, Low
|
|||||||
| BRVEBraveheart Bio, Inc. | 120 months$504M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Aug 6, 2026Underwritten, $383M | |
BRVE: 0 points, Low
|
|||||||
| MANEVeradermics, Inc | 128 months$798M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | May 1, 2026Private placement | |
MANE: 0 points, Low
|
|||||||
| PBLSParabilis Medicines, Inc. | 129 months$1.12B as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Jun 11, 2026Private placement | |
PBLS: 0 points, Low
|
|||||||
| INCYINCYTE CORP | 138 months$3.85B as of Sep 30, 2026 | None on file | None | +4% | None scheduled | None in 3 years | |
INCY: 0 points, Low
|
|||||||
| AGLagilon health, inc. | 194 months$240M as of Sep 30, 2026 | None on file | None | -96%split likely, not scored | None scheduled | None in 3 years | |
AGL: 0 points, Low
Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| GERNGERON CORP | 364 months$337M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | Mar 20, 2024Underwritten | |
GERN: 0 points, Low
|
|||||||
| BNTXBioNTech SE | 712 months$13.70B as of Dec 31, 2025 | None on file | None | +5% | None scheduled | None in 3 years | |
BNTX: 0 points, Low
|
|||||||
| ABCLAbCellera Biologics Inc. | No operating burn$764M as of Sep 30, 2026 | None on file | Feb 27, 2025S-3ASR | +9% | None scheduled | Aug 13, 2026Underwritten | |
ABCL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ACADACADIA PHARMACEUTICALS INC | No operating burn$976M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | None in 3 years | |
ACAD: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ACIUAC Immune SA | No operating burn$74M as of Dec 31, 2025 | Aug 6, 2024max $80Mfiled over 2 years ago | Mar 14, 2024F-3, $350M | +1% | None scheduled | Dec 15, 2023Underwritten, $50M | |
ACIU: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ADMAADMA BIOLOGICS, INC. | No operating burn$125M as of Sep 30, 2026 | None on file | None | -7% | None scheduled | None in 3 years | |
ADMA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| AKBAAkebia Therapeutics, Inc. | No operating burn$159M as of Sep 30, 2026 | Sep 3, 2024max $75Mfiled over 2 years ago | Sep 3, 2024S-3, $75M | +5% | None scheduled | Nov 16, 2026Private placement | |
AKBA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| BIIBBIOGEN INC. | No operating burn$1.30B as of Sep 30, 2026 | None on file | May 1, 2025S-3ASR | +1% | None scheduled | None in 3 years | |
BIIB: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CBIHCannabis Bioscience International Holdin | n/a$0.0M as of Feb 28, 2026 | None on file | None | +6% | None scheduled | None in 3 years | |
CBIH: 0 points, Low
|
|||||||
| IBOIMPACT BIOMEDICAL INC. | No operating burn$0.0M as of Sep 30, 2026 | None on file | None | -92%split likely, not scored | None scheduled | Sep 17, 2024Underwritten, $4.5M | |
IBO: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| IONSIONIS PHARMACEUTICALS INC | No operating burn$2.44B as of Sep 30, 2026 | Sep 10, 2024size not statedfiled over 2 years ago | None | +3% | None scheduled | Nov 17, 2025Private placement | |
IONS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| LLYELI LILLY & Co | No operating burn$4.89B as of Sep 30, 2026 | None on file | Feb 19, 2025S-3ASR | -1% | None scheduled | None in 3 years | |
LLY: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| LNTHLantheus Holdings, Inc. | No operating burn$684M as of Sep 30, 2026 | None on file | None | -1% | None scheduled | None in 3 years | |
LNTH: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| LQDALiquidia Corp | No operating burn$396M as of Sep 30, 2026 | None on file | Mar 5, 2026S-3ASR | +4% | None scheduled | Sep 12, 2024Private placement | |
LQDA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| OMEROMEROS CORP | No operating burn$95M as of Sep 30, 2026 | Nov 14, 2025max $150M | Nov 14, 2025S-3ASR | +5% | None scheduled | Jul 25, 2025Direct / best efforts | |
OMER: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PTCTPTC THERAPEUTICS, INC. | No operating burn$2.13B as of Sep 30, 2026 | None on file | None | +4% | None scheduled | Jun 18, 2026Private placement | |
PTCT: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| TECHBIO-TECHNE Corp | No operating burn$350M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
TECH: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| TVTXTravere Therapeutics, Inc. | No operating burn$472M as of Sep 30, 2026 | Nov 8, 2024max $100Mfiled over 2 years ago | Aug 1, 2024S-3ASR | +7% | None scheduled | May 11, 2026Private placement | |
TVTX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| VCREVicore Pharma Holding AB | n/a | None on file | None | n/a | None scheduled | None in 3 years | |
VCRE: 0 points, Low
|
|||||||
| VRTXVERTEX PHARMACEUTICALS INC / MA | No operating burn$9.82B as of Sep 30, 2026 | None on file | Feb 13, 2025S-3ASR | 0% | None scheduled | None in 3 years | |
VRTX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| BHCBausch Health Companies Inc. | No operating burn$2.49B as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
BHC: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ABBVAbbVie Inc. | No operating burn$10.77B as of Sep 30, 2026 | None on file | Feb 14, 2025S-3ASR | 0% | None scheduled | None in 3 years | |
ABBV: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ABTABBOTT LABORATORIES | No operating burn$4.30B as of Sep 30, 2026 | None on file | Feb 23, 2026S-3ASR | 0% | None scheduled | None in 3 years | |
ABT: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ABUSArbutus Biopharma Corp | No operating burn$337M as of Sep 30, 2026 | None on file | Nov 6, 2024S-3, $300M | -20% | None scheduled | None in 3 years | |
ABUS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ADRXADARx Pharmaceuticals, Inc. | No operating burn$901M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Sep 28, 2026Direct / best efforts, $446M | |
ADRX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| AMGNAMGEN INC | No operating burn$25.81B as of Sep 30, 2026 | None on file | Feb 13, 2026S-3ASR | +1% | None scheduled | None in 3 years | |
AMGN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| AMPHAmphastar Pharmaceuticals, Inc. | No operating burn$235M as of Sep 30, 2026 | None on file | None | -7% | None scheduled | None in 3 years | |
AMPH: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| AMRNAMARIN CORP PLC\UK | No operating burn$323M as of Sep 30, 2026 | None on file | None | -100%split likely, not scored | None scheduled | None in 3 years | |
AMRN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| AUPHAurinia Pharmaceuticals Inc. | No operating burn$487M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | None in 3 years | |
AUPH: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| BDRXBiodexa Pharmaceuticals Plc | n/aOffering filed Jul 1, 2026, after this date | None on file | Sep 26, 2025F-3, $100M | +3,278%split likely, not scored | None scheduled | Jul 1, 2026Direct / best efforts | |
BDRX: 0 points, Low
Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. An offering was filed after the balance-sheet date, so cash on hand is likely higher than shown. |
|||||||
| CAHCARDINAL HEALTH INC | No operating burn$5.26B as of Sep 30, 2026 | None on file | Aug 12, 2025S-3ASR | -3% | None scheduled | None in 3 years | |
CAH: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CCELCRYO CELL INTERNATIONAL INC | No operating burn$4.2M as of Aug 31, 2026 | None on file | None | +0% | None scheduled | None in 3 years | |
CCEL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| COLLCOLLEGIUM PHARMACEUTICAL, INC | No operating burn$145M as of Sep 30, 2026 | None on file | None | -2% | None scheduled | Dec 30, 2025Private placement | |
COLL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CORCencora, Inc. | No operating burn$2.82B as of Jun 30, 2026 | None on file | Nov 26, 2024S-3ASR | -2% | None scheduled | None in 3 years | |
COR: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CPIXCUMBERLAND PHARMACEUTICALS INC | No operating burn$3.9M as of Sep 30, 2026 | Feb 14, 2025max $5.8M | Dec 14, 2023S-3, $100M | +0% | None scheduled | Mar 20, 2024Direct / best efforts | |
CPIX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CRLCHARLES RIVER LABORATORIES INTERNATIONAL | No operating burn$200M as of Sep 26, 2026 | None on file | May 9, 2024S-3ASR | -3% | None scheduled | None in 3 years | |
CRL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| DVADAVITA INC. | No operating burn$605M as of Sep 30, 2026 | None on file | None | -11% | None scheduled | None in 3 years | |
DVA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| EBSEmergent BioSolutions Inc. | No operating burn$176M as of Sep 30, 2026 | None on file | Aug 7, 2025S-3, $250M | -2% | None scheduled | Apr 17, 2026Private placement | |
EBS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ESYNEnerSyn Global Inc. | No operating burn$1.6M as of Sep 30, 2026 | None on file | None | +421%split likely, not scored | None scheduled | Aug 10, 2026Private placement | |
ESYN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count rose more than fourfold in a year; this can be a split or share conversion rather than new issuance, so it is not scored. |
|||||||
| ETRAElectra Therapeutics, Inc. | No operating burn$409M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Sep 18, 2026Underwritten, $350M | |
ETRA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| FMSFresenius Medical Care AG | n/a | None on file | None | -5% | None scheduled | None in 3 years | |
FMS: 0 points, Low
|
|||||||
| ICCCIMMUCELL CORP /DE/ | No operating burn$7.9M as of Sep 30, 2026 | Apr 1, 2024max $11Mfiled over 2 years ago | Apr 1, 2024S-3, $11M | +1% | None scheduled | None in 3 years | |
ICCC: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| IDXXIDEXX LABORATORIES INC /DE | No operating burn$198M as of Sep 30, 2026 | None on file | None | -1% | None scheduled | None in 3 years | |
IDXX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| INVAInnoviva, Inc. | No operating burn$1.13B as of Sep 30, 2026 | None on file | None | -5% | None scheduled | None in 3 years | |
INVA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| IQVIQVIA HOLDINGS INC. | No operating burn$2.42B as of Sep 30, 2026 | None on file | None | -3% | None scheduled | None in 3 years | |
IQV: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| IRWDIRONWOOD PHARMACEUTICALS INC | No operating burn$86M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | None in 3 years | |
IRWD: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| MEDPMedpace Holdings, Inc. | No operating burn$705M as of Sep 30, 2026 | None on file | None | -1% | None scheduled | None in 3 years | |
MEDP: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| MRVIMARAVAI LIFESCIENCES HOLDINGS, INC. | No operating burn$73M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | None in 3 years | |
MRVI: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| NATRNATURES SUNSHINE PRODUCTS INC | No operating burn$89M as of Sep 30, 2026 | None on file | None | -1% | None scheduled | None in 3 years | |
NATR: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| NBIXNEUROCRINE BIOSCIENCES INC | No operating burn$790M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | None in 3 years | |
NBIX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| NRCNRC HEALTH | No operating burn$3.6M as of Sep 30, 2026 | None on file | None | -6% | None scheduled | None in 3 years | |
NRC: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| OBXObsidian Therapeutics, Inc. | No operating burn$324M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Aug 3, 2026Private placement | |
OBX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ORMPORAMED PHARMACEUTICALS INC. | No operating burn$40M as of Sep 30, 2026 | None on file | None | +9% | None scheduled | Mar 18, 2024Direct / best efforts | |
ORMP: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PAHCPHIBRO ANIMAL HEALTH CORP | No operating burn$83M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | None in 3 years | |
PAHC: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PARKPark Dental Partners, Inc. | No operating burn$23M as of Sep 30, 2026 | None on file | None | n/a | None scheduled | Nov 9, 2026Private placement | |
PARK: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PBHPrestige Consumer Healthcare Inc. | No operating burn$47M as of Sep 30, 2026 | None on file | None | -1% | None scheduled | None in 3 years | |
PBH: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PBYIPUMA BIOTECHNOLOGY, INC. | No operating burn$109M as of Sep 30, 2026 | None on file | None | +3% | None scheduled | None in 3 years | |
PBYI: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PGNYProgyny, Inc. | No operating burn$196M as of Sep 30, 2026 | None on file | None | -15% | None scheduled | None in 3 years | |
PGNY: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PRGOPERRIGO Co plc | No operating burn$437M as of Sep 26, 2026 | None on file | Sep 9, 2024S-3ASR | +1% | None scheduled | None in 3 years | |
PRGO: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PTGXProtagonist Therapeutics, Inc | No operating burn$835M as of Sep 30, 2026 | None on file | Aug 6, 2025S-3ASR | +4% | None scheduled | None in 3 years | |
PTGX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| RDYDR REDDYS LABORATORIES LTD | No operating burn$76.24B as of Mar 31, 2026 | None on file | None | 0% | None scheduled | None in 3 years | |
RDY: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| RMTIROCKWELL MEDICAL, INC. | No operating burn$23M as of Sep 30, 2026 | Nov 13, 2024max $25Mfiled over 2 years ago | Oct 8, 2024S-3, $100M | -88%split likely, not scored | None scheduled | Nov 3, 2026Private placement | |
RMTI: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| RPRXRoyalty Pharma plc | No operating burn$895M as of Sep 30, 2026 | None on file | Jun 3, 2024S-3ASR | n/a | None scheduled | Jan 10, 2025Private placement | |
RPRX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| SHCSotera Health Co | No operating burn$412M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
SHC: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| SIGASIGA TECHNOLOGIES INC | No operating burn$116M as of Sep 30, 2026 | None on file | None | +0% | None scheduled | None in 3 years | |
SIGA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| TAKTAKEDA PHARMACEUTICAL CO LTD | No operating burn$418.53B as of Mar 31, 2026 | None on file | Jun 25, 2025F-3ASR | -1% | None scheduled | None in 3 years | |
TAK: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| VMDVIEMED HEALTHCARE, INC. | No operating burn$9.7M as of Sep 30, 2026 | None on file | None | 0% | None scheduled | None in 3 years | |
VMD: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ZVRAZEVRA THERAPEUTICS, INC. | No operating burn$271M as of Sep 30, 2026 | None on file | Jun 4, 2024S-3, $350M | +6% | None scheduled | Aug 9, 2024Underwritten, $60M | |
ZVRA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ZYBTZhengye Biotechnology Holding Ltd | No operating burn$52M as of Dec 31, 2025 | None on file | None | +4% | None scheduled | Jan 7, 2025Underwritten, $6.0M | |
ZYBT: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ADPTAdaptive Biotechnologies Corp | No operating burn$400M as of Sep 30, 2026 | None on file | None | +6% | None scheduled | Jun 22, 2026Private placement | |
ADPT: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ALKSAlkermes plc. | No operating burn$787M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | None in 3 years | |
ALKS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ALNYALNYLAM PHARMACEUTICALS, INC. | No operating burn$3.59B as of Sep 30, 2026 | None on file | None | +1% | None scheduled | Sep 12, 2025Private placement | |
ALNY: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ANIPANI PHARMACEUTICALS INC | No operating burn$421M as of Sep 30, 2026 | None on file | None | -80%split likely, not scored | None scheduled | Sep 26, 2025Private placement | |
ANIP: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ASNDAscendis Pharma A/S | No operating burn$964M as of Dec 31, 2025 | None on file | Sep 18, 2024F-3ASR | +2% | None scheduled | Sep 20, 2024Underwritten, $300M | |
ASND: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| EXELEXELIXIS, INC. | No operating burn$1.52B as of Oct 2, 2026 | None on file | None | -9% | None scheduled | None in 3 years | |
EXEL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| GSKGSK plc | No operating burn$2.96B as of Dec 31, 2025 | None on file | Mar 25, 2024F-3ASR | 0% | None scheduled | None in 3 years | |
GSK: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| IXHLIncannex Healthcare Inc. | No operating burn$68M as of Sep 30, 2026 | Jul 24, 2025max $100M | Nov 6, 2024S-3, $150M | -96%split likely, not scored | None scheduled | Mar 12, 2026Direct / best efforts, $108M | |
IXHL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| ROIVRoivant Sciences Ltd. | No operating burn$4.21B as of Sep 30, 2026 | Oct 3, 2025max $400M | Oct 3, 2025S-3ASR, $400M | +4% | None scheduled | None in 3 years | |
ROIV: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CGENCOMPUGEN LTD | No operating burn$118M as of Dec 31, 2025 | May 18, 2026max $400M | May 18, 2026F-3, $100M | +6% | None scheduled | None in 3 years | |
CGEN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CAPSCapstone Holding Corp. | No operating burn$0.6M as of Sep 30, 2026 | None on file | None | -89%split likely, not scored | None scheduled | Jun 12, 2026Private placement | |
CAPS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| CRMDCorMedix Inc. | No operating burn$355M as of Sep 30, 2026 | May 9, 2024max $50Mfiled over 2 years ago | May 9, 2024S-3, $50M | +1% | None scheduled | Nov 9, 2026Private placement | |
CRMD: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| CYRXCryoport, Inc. | No operating burn$393M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
CYRX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ELANElanco Animal Health Inc | No operating burn$465M as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
ELAN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| GMABGENMAB A/S | No operating burn$1.87B as of Dec 31, 2025 | None on file | None | n/a | None scheduled | None in 3 years | |
GMAB: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| GRFSGrifols SA | No operating burn$486M as of Dec 31, 2025 | None on file | None | n/a | None scheduled | None in 3 years | |
GRFS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| HALOHALOZYME THERAPEUTICS, INC. | No operating burn$1.07B as of Sep 30, 2026 | None on file | None | -3% | None scheduled | Sep 22, 2026Private placement | |
HALO: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| HCMHUTCHMED (China) Ltd | No operating burn$1.38B as of Dec 31, 2025 | None on file | Jun 28, 2024F-3ASR | +0% | None scheduled | None in 3 years | |
HCM: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| HLFHERBALIFE LTD. | No operating burn$409M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | None in 3 years | |
HLF: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ICLRICON PLC | No operating burn$809M as of Jun 30, 2026 | None on file | Apr 26, 2024F-3ASR | -5% | None scheduled | None in 3 years | |
ICLR: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| IMCRImmunocore Holdings plc | No operating burn$901M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | Feb 2, 2024Private placement | |
IMCR: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| OCSOculis Holding AG | No operating burn$210M as of Dec 31, 2025 | Nov 3, 2026max $125M | Mar 4, 2026F-3ASR, $100M | n/a | None scheduled | Oct 31, 2025Direct / best efforts | |
OCS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| INDVSupernus, Inc. | No operating burn$305M as of Sep 30, 2026 | None on file | None | -6% | None scheduled | Mar 17, 2026Private placement | |
INDV: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| JNJJOHNSON & JOHNSON | No operating burn$20.37B as of Sep 27, 2026 | None on file | Feb 11, 2026S-3ASR | 0% | None scheduled | None in 3 years | |
JNJ: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| KMDAKAMADA LTD | No operating burn$70M as of Dec 31, 2025 | None on file | Sep 9, 2026F-3 | +0% | None scheduled | None in 3 years | |
KMDA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| KNSAKiniksa Pharmaceuticals International, p | No operating burn$576M as of Sep 30, 2026 | None on file | Jun 28, 2024S-3, $400M | n/a | None scheduled | None in 3 years | |
KNSA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| KRYSKrystal Biotech, Inc. | No operating burn$912M as of Sep 30, 2026 | None on file | None | +2% | None scheduled | None in 3 years | |
KRYS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| LFCRLIFECORE BIOMEDICAL, INC. \DE\ | No operating burn$23M as of Sep 30, 2026 | None on file | Sep 23, 2025S-3, $150M | +1% | None scheduled | Oct 4, 2024Private placement | |
LFCR: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| LFVNLifevantage Corp | No operating burn$14M as of Sep 30, 2026 | None on file | Mar 10, 2026S-3, $75M | 0% | None scheduled | None in 3 years | |
LFVN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| MDGLMADRIGAL PHARMACEUTICALS, INC. | No operating burn$961M as of Sep 30, 2026 | May 7, 2024max $300Mfiled over 2 years ago | May 7, 2024S-3ASR | +2% | None scheduled | Mar 20, 2024Underwritten | |
MDGL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| NEOGNEOGEN CORP | No operating burn$172M as of Aug 31, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
NEOG: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| NUSNU SKIN ENTERPRISES, INC. | No operating burn$167M as of Sep 30, 2026 | None on file | None | 0% | None scheduled | None in 3 years | |
NUS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| NVONOVO NORDISK A S | No operating burn$46.35B as of Dec 31, 2025 | None on file | None | n/a | None scheduled | None in 3 years | |
NVO: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| NVSNOVARTIS AG | No operating burn$8.87B as of Dec 31, 2025 | None on file | Sep 16, 2024F-3ASR | -3% | None scheduled | None in 3 years | |
NVS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| OABIOmniAb, Inc. | No operating burn$64M as of Sep 30, 2026 | Dec 8, 2023max $100Mfiled over 2 years ago | Dec 8, 2023S-3, $100M | +1% | None scheduled | Aug 25, 2025Private placement | |
OABI: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| OGNOrganon & Co. | No operating burn$1.46B as of Sep 30, 2026 | None on file | None | +1% | None scheduled | None in 3 years | |
OGN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ONCBeOne Medicines Ltd. | No operating burn$5.78B as of Sep 30, 2026 | None on file | None | +3% | None scheduled | May 13, 2025Private placement | |
ONC: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| PFEPFIZER INC | No operating burn$11.00B as of Sep 27, 2026 | None on file | Feb 23, 2024S-3ASR | +0% | None scheduled | None in 3 years | |
PFE: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| QGENQIAGEN N.V. | No operating burn$833M as of Dec 31, 2025 | None on file | None | -2% | None scheduled | None in 3 years | |
QGEN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| REGNREGENERON PHARMACEUTICALS, INC. | No operating burn$18.86B as of Sep 30, 2026 | None on file | Oct 31, 2024S-3ASR | +5% | None scheduled | None in 3 years | |
REGN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| RIGLRIGEL PHARMACEUTICALS INC | No operating burn$121M as of Sep 30, 2026 | Aug 2, 2024max $100Mfiled over 2 years ago | Aug 2, 2024S-3, $100M | +4% | None scheduled | None in 3 years | |
RIGL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| RLYBRallybio Corp | No operating burn$179M as of Sep 30, 2026 | Mar 13, 2025max $9.6M | None | -87%split likely, not scored | None scheduled | Jun 1, 2026Private placement | |
RLYB: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. Share count fell by more than half in a year, which usually means a reverse split; share growth is not scored. |
|||||||
| SNYSanofi | No operating burn$5.97B as of Dec 31, 2025 | None on file | Apr 4, 2024F-3ASR | -4% | None scheduled | None in 3 years | |
SNY: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| SRPTSarepta Therapeutics, Inc. | No operating burn$879M as of Sep 30, 2026 | None on file | Mar 3, 2025S-3ASR | +2% | None scheduled | Dec 11, 2025Private placement | |
SRPT: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| TGTXTG THERAPEUTICS, INC. | No operating burn$505M as of Sep 30, 2026 | None on file | Aug 8, 2025S-3ASR | -5% | None scheduled | None in 3 years | |
TGTX: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| UTHRUNITED THERAPEUTICS Corp | No operating burn$3.54B as of Sep 30, 2026 | None on file | None | -1% | None scheduled | None in 3 years | |
UTHR: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| VCELVericel Corp | No operating burn$236M as of Sep 30, 2026 | None on file | Aug 16, 2024S-3ASR | +1% | None scheduled | None in 3 years | |
VCEL: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| VTRSViatris Inc | No operating burn$1.79B as of Sep 30, 2026 | None on file | None | -1% | None scheduled | None in 3 years | |
VTRS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| ZTSZoetis Inc. | No operating burn$1.53B as of Sep 30, 2026 | None on file | Aug 5, 2025S-3ASR | -8% | None scheduled | Dec 18, 2025Private placement | |
ZTS: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| TEVATEVA PHARMACEUTICAL INDUSTRIES LTD | No operating burn$4.09B as of Sep 30, 2026 | None on file | Feb 7, 2025S-3ASR | +2% | None scheduled | None in 3 years | |
TEVA: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| MCKMCKESSON CORP | No operating burn$6.53B as of Sep 30, 2026 | None on file | Feb 5, 2026S-3ASR | -7% | None scheduled | None in 3 years | |
MCK: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| MRKMerck & Co., Inc. | No operating burn$11.25B as of Sep 30, 2026 | None on file | Mar 19, 2024S-3ASR | -1% | None scheduled | May 20, 2026Convertible | |
MRK: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
| SUPNSupernus, Inc. | No operating burn$305M as of Sep 30, 2026 | None on file | None | -6% | None scheduled | Mar 17, 2026Private placement | |
SUPN: 0 points, Low
No operating cash burn in the latest filings, so runway and financing tools are not scored. |
|||||||
New financing filings, last 30 days
- Nov 17, 2026 · ALLR · Private placement (8-K Item 3.02) · 8-K
- Nov 17, 2026 · AZR · Shelf registration with ATM program, max $20M · S-3
- Nov 17, 2026 · ADIL · Shelf registration with ATM program, max $20M · S-3
- Nov 16, 2026 · TTRX · ATM program, max $50M · 424B5
- Nov 16, 2026 · IMDX · Underwritten offering · 424B5
- Nov 16, 2026 · ACRV · Shelf registration, max $300M · S-3
- Nov 16, 2026 · MPLT · Shelf registration with ATM program, max $100M · S-3
- Nov 16, 2026 · ARCT · Private placement (8-K Item 3.02) · 8-K
- Nov 16, 2026 · SRZN · ATM program, max $50M · 424B5
- Nov 16, 2026 · AKBA · Private placement (8-K Item 3.02) · 8-K
- Nov 16, 2026 · MDCX · Private placement (8-K Item 3.02) · 8-K
- Nov 16, 2026 · MEDS · ATM program, max $10M · 424B5
- Nov 16, 2026 · VIR · Underwritten offering, $150M · 424B5
- Nov 16, 2026 · RZLT · Underwritten offering · 424B5
- Nov 16, 2026 · MDCX · Registered direct / best-efforts offering, $3.0M · 424B5
- Nov 13, 2026 · DCOY · Shelf registration · S-3
- Nov 13, 2026 · INBX · Shelf registration with ATM program, max $150M · S-3ASR
- Nov 12, 2026 · VOR · Private placement (8-K Item 3.02) · 8-K
- Nov 12, 2026 · VIR · Shelf registration · S-3ASR
- Nov 12, 2026 · VIR · Underwritten offering · 424B5
- Nov 12, 2026 · TLPH · Shelf registration · S-3
- Nov 12, 2026 · PROK · Registered direct / best-efforts offering · 424B5
- Nov 12, 2026 · PRME · Underwritten offering, $125M · 424B5
- Nov 12, 2026 · PEPG · Underwritten offering, $125M · 424B5
- Nov 12, 2026 · MGTX · Shelf registration with ATM program, max $100M · S-3ASR
How the score works
The Dilution Pressure score runs from 0 to 100 and is the sum of named, rule-based components. Nothing is estimated by a model.
- Cash runway, up to 40 points: 40 at six months or less, 30 at twelve, 18 at eighteen, 8 at twenty-four. Runway is cash, cash equivalents and marketable securities divided by operating cash burn, both from the latest 10-Q or 10-K. Companies with no operating burn score zero here and on financing tools.
- ATM program on file, 15 points: an at-the-market sales agreement filed in the last three years (424B5 supplement, or an ATM prospectus inside an S-3).
- Shelf registration, 10 points: an S-3, S-3ASR, F-3 or F-3ASR in the last three years; an S-1 registration in the last year scores 8 instead. Resale shelves for selling stockholders do not count.
- Share count growth, up to 20 points: shares outstanding from the 10-Q and 10-K cover pages compared with a year earlier: 20 at +50% or more, 14 at +25%, 7 at +10%. Changes that look like splits are flagged and not scored.
- FDA decision ahead, up to 15 points: 15 if a PDUFA date falls within 90 days, 8 within 180.
- Minus 10 points when an offering was filed after the last reported balance sheet, because the runway figure then understates the cash on hand.
Levels: High 60 and above, Elevated 40 to 59, Moderate 20 to 39, Low below 20. The universe is limited to companies classified as biotech or pharma by their SEC industry code or Nasdaq industry, or that have an FDA application or drug program in our data.
Limits worth knowing. An ATM figure is the program maximum; how much has already been sold is disclosed only in quarterly reports and is not subtracted, and an older program may be used up or replaced. Filing types are classified automatically from the document text and can be wrong, which is why every row links to the filing itself. Straight debt offerings and resale registrations are excluded. Read more about dilution in biotech stocks, or see how prices behave around upcoming FDA decisions and past ones.
Know the day a company you follow files for a raise
BioRadar emails you when a stock on your watchlist files a shelf, an ATM program or an offering, alongside PDUFA countdowns and daily AI briefings. Included in the 7-day free trial: card required, $15 a month after, cancel anytime.
Start 7-day free trial →Frequently asked questions
What is the BioRadar dilution pressure score?
A 0 to 100 gauge built from public SEC filings: cash runway (up to 40 points), an at-the-market program on file (15), a shelf registration (10), share-count growth over the past year (up to 20) and an FDA decision within 180 days (up to 15), minus 10 when an offering was filed after the last reported balance sheet. It measures the need and the capacity to issue shares, not a forecast.
Which biotech companies have an ATM program on file?
439 of the 729 biotech and pharma companies BioRadar tracks have filed an at-the-market program in the last three years. The highest pressure scores among them belong to CVKD, PYPD, COSM, GNLX, ANVS. The size shown is the program maximum when filed; how much remains is not disclosed in structured filings. The full list links to each filing and is checked daily.
Why do biotech companies often raise money right after good news?
Share price and trading volume are usually highest right after positive trial data or an FDA approval, so a raise then costs the fewest new shares. Companies that already have a shelf registration or an ATM program can sell within hours, which is why thin cash, a financing tool on file and an upcoming FDA decision is the combination BioRadar flags.
Is a high dilution pressure score a sell signal?
No. A high score says a company needs cash and has the paperwork in place to raise it. Whether a raise hurts the stock depends on its size, price and timing, and a well-funded company can still fall on bad data. Use the score as one input and read the filings behind it.